---
layout: default
title: episode_object_concept_id
parent: Episode
grand_parent: Transformation Documentation
has_toc: false
---
# episode_object_concept_id
### SACT Episode
Source column  `Regimen`.
Lookup Cancer treatment regimens concept.


|Regimen|episode_object_concept_id|notes|
|------|-----|-----|
|BEAM|35803616|BEAM|
|CAV|35806944|CAV|
|ChlVPP|35805822|ChlVPP|
|ICE|35805126|ICE|
|PCV|35803682|PCV|
|PEI|912256|PEI|
|R-CODOX-M / R-IVAC|35804381|R-CODOX-M/R-IVAC|
|R-CP|35806665|R-CP|
|R-DHAOx|35805057|R-DHAOx|
|R-GCVP|35805041|R-GCVP|
|MACE|37557218|MACE|
|MMM|1524957|MMM|
|FLAG-IDA|35803457|FLAG-Ida|
|FLAG|35803501|FLAG|
|MATRix|35804413|MATRix|
|VCP|35806343|VCP|
|VDC/IE|35805450|VDC/IE|
|TIP|35806625|TIP|
|ATRA / Arsenic Trioxide|35803549|Arsenic trioxide and ATRA|
|ATRA Arsenic trioxide|35803549|Arsenic trioxide and ATRA|
|Everolimus Lenvatinib|35806906|Everolimus and Lenvatinib|
|Docetaxel Nintedanib|42542355|Docetaxel and Nintedanib|
|Idelalisib Rituximab|35804590|Idelalisib and Rituximab|
|Olaparib Bevacizumab|912013|Olaparib and Bevacizumab|
|Temozolomide Capecitabine|35806577|Capecitabine and Temozolomide|
|Nintedanib Docetaxel|42542355|Docetaxel and Nintedanib|
|Temozolomide Irinotecan|35805455|Irinotecan and Temozolomide|
|Abemaciclib Fulvestrant|35804294|Abemaciclib and Fulvestrant|
|Alpelisib Fulvestrant|35101866|Alpelisib and Fulvestrant|
|Encorafenib Binimetinib|35806137|Binimetinib and Encorafenib|
|Pemetrexed Cisplatin|35806173|Cisplatin and Pemetrexed|
|Dacarbazine Gemcitabine|35806969|Dacarbazine and Gemcitabine|
|Avelumab Axitinib|35806900|Axitinib and Avelumab|
|Ipilimumab Nivolumab|35806133|Ipilimumab-Nivolumab|
|Irinotecan Temozolomide|35805455|Irinotecan and Temozolomide|
|Docetaxel Prednisolone|35102022|Docetaxel and Prednisolone|
|Venetoclax Azacitidine|35803466|Azacitidine and Venetoclax|
|Atezolizumab Bevacizumab|35806408|Atezolizumab and Bevacizumab|
|Ibrutinib Venetoclax|35806097|Ibrutinib and Venetoclax|
|Melphalan +/- Prednisolone|35806351|Melphalan and Methylprednisolone|
|Cyclophosphamide Prednisolone|35803428|Cyclophosphamide and Prednisolone|
|Ifosfamide Doxorubicin|35806965|Doxorubicin and Ifosfamide|
|Obinutuzumab Bendamustine|35804585|Bendamustine and Obinutuzumab|
|Cyclophosphamide Etoposide|35806476|Cyclophosphamide and Etoposide|
|Cetuximab Encorafenib|911998|Encorafenib and Cetuximab|
|Obinutuzumab Venetoclax|35100084|Venetoclax and Obinutuzumab|
|Gemcitabine Docetaxel|35803577|Docetaxel and Gemcitabine|
|Ramucirumab Paclitaxel|35805371|Paclitaxel and Ramucirumab|
|Brentuximab vedotin|35803702|Brentuximab vedotin monotherapy|
|Trifluridine-Tipiracil|35804789|Trifluridine and tipiracil monotherapy|
|Pomalidomide Dexamethasone|42542407|Pomalidomide and Dexamethasone (Pd)|
|Dabrafenib Trametinib|35804100|Dabrafenib and Trametinib|
|Vinblastine Methotrexate|1525155|Methotrexate and Vinblastine|
|Mitomycin Capecitabine + RT|35803671|Capecitabine, Mitomycin, RT|
|Ribociclib Fulvestrant|35804285|Fulvestrant and Ribociclib|
|Mitomycin Capecitabine|35804560|Capecitabine and Mitomycin|
|Tucatinib Capecitabine Trastuzumab|911925|Capecitabine and Trastuzumab (XH) and Tucatinib|
|Venetoclax Rituximab|35804605|Venetoclax and Rituximab|
|Cisplatin Capecitabine + RT|35805336|Capecitabine, Cisplatin, RT|
|Palbociclib Fulvestrant|35804297|Fulvestrant and Palbociclib|
|Carfilzomib Dexamethasone|35806309|Carfilzomib and Dexamethasone (Kd)|
|Sacituzumab govitecan|912024|Sacituzumab govitecan monotherapy|
|Plerixafor + G-CSF Priming|35101641|Plerixafor and G-CSF|
|Ifosfamide Etoposide and HD Methotrexate|35805125|Etoposide, Ifosfamide, Methotrexate|
|Bevacizumab Irinotecan|35803693|Irinotecan and Bevacizumab|
|Pomalidomide + low dose Dexamethasone|42542407|Pomalidomide and Dexamethasone (Pd)|
|Paclitaxel weekly|35804205|Paclitaxel monotherapy, weekly|
|Paclitaxel (90) weekly|35804205|Paclitaxel monotherapy, weekly|
|Temozolomide with concurrent RT|35803687|Temozolomide and RT, then Temozolomide|
|Melphalan intermediate dose with Dexamethasone|905703|Melphalan and Dexamethasone|
|Ipilimumab Nivolumab (melanoma)|35806133|Ipilimumab-Nivolumab|
|EC Docetaxel|1525058|EC-TL (Docetaxel)|
|FEC (100)|35804212|FEC|
|Docetaxel Cyclophosphamide|35804232|Cyclophosphamide and Docetaxel (TC)|
|Capecitabine (5 day) with RT|35806890|Capecitabine and RT|
|Paclitaxel albumin-bound|35804167|Paclitaxel, nanoparticle albumin-bound monotherapy|
|Cyclophosphamide po daily +/- Prednisolone|35803428|Cyclophosphamide and Prednisolone|
|Panobinostat Bortezomib Dexamethasone (PanBorDex)|35806306|Bortezomib and Dexamethasone (Vd) and Panobinostat|
|CHOEP-21 bolus|35803698|CHOEP-21|
|R-ESHAP (daypatient)|35805061|R-ESHAP|
|R-mini CHOP|35805028|R-CHOP|
|Gemcitabine Capecitabine|35804557|Capecitabine and Gemcitabine|
|Cisplatin Etoposide|35805329|Cisplatin and Etoposide (EP)|
|EC Docetaxel Trastuzumab|37560133|EC-TH (Docetaxel) (trastuzumab-dttb)|
|CAV (SCLC)|35806944|CAV|
|Nivolumab Brentuximab vedotin (compassionate use)|35805828|Brentuximab vedotin and Nivolumab|
|Paclitaxel weekly (relapsed/metastatic)|35804205|Paclitaxel monotherapy, weekly|
|R-ESHAP (inpatient)|35805061|R-ESHAP|
|Temozolomide with concurrent RT (support)|35803687|Temozolomide and RT, then Temozolomide|
|Lenalidomide Dexamethasone|35806053|Lenalidomide and Dexamethasone (Rd)|
|Azacitidine|35803465|Azacitidine monotherapy|
|FOLFIRINOX (adjuvant)|35804771|FOLFIRINOX|
|Paclitaxel (weekly for 3 weeks then 1 week off)|35804205|Paclitaxel monotherapy, weekly|
|Vinorelbine (IV) Carboplatin (CrCl)|35806405|Carboplatin and Vinorelbine|
|Cyclophosphamide po weekly +/- Prednisolone|35803428|Cyclophosphamide and Prednisolone|
|Brentuximab vedotin (compassionate use)|35805828|Brentuximab vedotin and Nivolumab|
|R-ICE modified|35805063|R-ICE|
|Paclitaxel weekly (sarcoma)|35804205|Paclitaxel monotherapy, weekly|
|Obinutuzumab Chlorambucil|35804572|Chlorambucil and Obinutuzumab (GClb)|
|Gemcitabine with RT (bladder)|35804152|Gemcitabine and RT|
|Avelumab|35804159|Avelumab monotherapy|
|Trastuzumab Cisplatin Capecitabine|35805363|Capecitabine and Cisplatin (CX) and Trastuzumab|
|Rituximab Gemcitabine Oxaliplatin (R-GemOx)|37559706|R-GemOx (rituximab-rixa)|
|Irinotecan Temozolomide Vincristine|35805455|Irinotecan and Temozolomide|
|Cyclophosphamide TBI (Allograft)|35803613|Cyclophosphamide and TBI|
|FEC (100) Docetaxel (100)|1525108|FEC-TH (Docetaxel)|
|Vinorelbine (oral) Carboplatin (CrCl)|35806405|Carboplatin and Vinorelbine|
|Vinorelbine (oral) Trastuzumab|35804242|Vinorelbine and Trastuzumab (VH)|
|Apixaban|35807094|Apixaban monotherapy|
|Talimogene laherparepvec|35806121|Talimogene laherparepvec monotherapy|
|Everolimus|35805075|Everolimus monotherapy|
|Melphalan PO +/- Prednisolone|35806351|Melphalan and Methylprednisolone|
|Capecitabine with concurrent RT|35806890|Capecitabine and RT|
|Venetoclax Azacitidine (unsuitable for intensive treatment)|35803466|Azacitidine and Venetoclax|
|Encorafenib Binimetinib (compassionate use)|35806137|Binimetinib and Encorafenib|
|Cisplatin Fluorouracil (CF100)|35803676|Cisplatin and Fluorouracil (CF)|
|Paclitaxel albumin-bound Trastuzumab|35804167|Paclitaxel, nanoparticle albumin-bound monotherapy|
|VDTPACE|35806327|DTPACE|
|Pomalidomide Dexamethasone (compassionate use)|42542407|Pomalidomide and Dexamethasone (Pd)|
|Vinorelbine (oral) Carboplatin (EDTA)|35806398|Carboplatin, Vinorelbine, RT|
|Paclitaxel weekly for 3 weeks then 1 week off|35804205|Paclitaxel monotherapy, weekly|
|STELLAR Acalabrutinib monotherapy (Trial)|35804606|Acalabrutinib monotherapy|
|R-CHOP-14 bolus|35805031|R-CHOP-14|
|Temozolomide 75 + RT|35803686|Temozolomide and RT|
|Romidepsin (compassionate use)|35804817|Romidepsin monotherapy|
|Gemcitabine (1250) Cisplatin|35806427|Cisplatin and Gemcitabine/Erlotinib|
|Ipilimumab|35806133|Ipilimumab-Nivolumab|
|Cyclophosphamide Vincristine Dacarbazine (CVD)|35806646|Cyclophosphamide, Dacarbazine, Vincristine|
|Cisplatin Capecitabine with concurrent RT|1525040|Capecitabine and Cisplatin (CX) and RT|
|Capecitabine Trastuzumab|35804312|Capecitabine and Trastuzumab (XH)|
|Busulfan Cyclophosphamide (Allograft)|35806362|Busulfan and Cyclophosphamide, then allo HSCT|
|R-CVP bolus|35805630|R-CVP|
|Lorlatinib|35806425|Lorlatinib monotherapy|
|Panobinostat Bortezomib weekly Dexamethasone (PanBorDex)|35806306|Bortezomib and Dexamethasone (Vd) and Panobinostat|
|Nintedanib|37557063|Nintedanib monotherapy|
|Dasatinib|35804080|Dasatinib monotherapy|
|IMMU-132-13 Sacituzumab govitecan (Trial)|912024|Sacituzumab govitecan monotherapy|
|Axitinib|37560929|Axitinib and Toripalimab|
|Midostaurin (compassionate use)|35803513|Midostaurin monotherapy|
|Capecitabine (5 day) with RT (pancreas)|35806890|Capecitabine and RT|
|BEAM (ambulatory)|35803616|BEAM|
|Dacomitinib|35806428|Dacomitinib monotherapy|
|Dabrafenib Trametinib (metastatic)|35804100|Dabrafenib and Trametinib|
|Fludarabine Melphalan Alemtuzumab (60 late) RIC|35803629|Fludarabine, Melphalan, Alemtuzumab|
|Avelumab Axitinib (EAMS)|35806900|Axitinib and Avelumab|
|Paclitaxel Carboplatin (CrCl) with concurrent RT|35805350|Carboplatin and Paclitaxel (CP) and RT|
|FEC (100) Docetaxel (75) Pertuzumab Trastuzumab (neoadjuvant)|37560136|FEC-THP (Docetaxel) (trastuzumab-dttb)|
|Cisplatin Capecitabine|35805335|Capecitabine and Cisplatin (CX)|
|Temozolomide Irinotecan (TEMIRI)|35805455|Irinotecan and Temozolomide|
|Durvalumab|35804164|Durvalumab monotherapy|
|Cisplatin Fluorouracil (CF80)|35803676|Cisplatin and Fluorouracil (CF)|
|Regorafenib|35804569|Regorafenib monotherapy|
|Ipilimumab Nivolumab (mesothelioma)|35806133|Ipilimumab-Nivolumab|
|rEECur Carboplatin Etoposide (CE) (NCRN Trial)|35806400|Carboplatin and Etoposide (CE)|
|Cisplatin Etoposide with concurrent RT (SCLC)|35805334|Cisplatin, Etoposide, RT|
|Atezolizumab Bevacizumab Paclitaxel Carboplatin (CrCl)|37561589|Carboplatin and Paclitaxel (CP), Atezolizumab, Bevacizumab-aveg|
|Carboplatin Pemetrexed (CrCl)|35806172|Carboplatin and Pemetrexed|
|Carboplatin with concurrent RT (CrCl)|35804530|Carboplatin and RT|
|Ruxolitinib|35803508|Ruxolitinib monotherapy|
|Cyclophosphamide oral +/- Methotrexate|35101986|Cyclophosphamide and Methotrexate (CM)|
|Enzalutamide|35804322|Enzalutamide monotherapy|
|Clarithromycin prophylaxis|35806104|Clarithromycin monotherapy|
|Asciminib (compassionate use)|1524898|Asciminib monotherapy|
|Paclitaxel weekly for 3 weeks then 1 week off (sarcoma)|35804205|Paclitaxel monotherapy, weekly|
|Bosutinib|35804082|Bosutinib monotherapy|
|Ceritinib|35804391|Ceritinib monotherapy|
|Gemcitabine (675) Docetaxel (70) (sarcoma)|35803577|Docetaxel and Gemcitabine|
|Pazopanib|37557053|Pazopanib/Everolimus|
|Gilteritinib|35803515|Gilteritinib monotherapy|
|Rucaparib|35806484|Rucaparib monotherapy|
|Inotuzumab ozogamicin cycle 1|35804064|Inotuzumab ozogamicin monotherapy|
|ORACLE Azacitidine (Trial)|35803465|Azacitidine monotherapy|
|Carboplatin Etoposide (EDTA)|35806400|Carboplatin and Etoposide (CE)|
|Zoledronic acid 6 weekly (support)|35806301|Zoledronic acid therapy|
|Lutetium-177 vipivotide tetraxetan (without support medication) (EAMS)|1525150|Lutetium Lu 177 vipivotide tetraxetan monotherapy|
|Mobocertinib|1525157|Mobocertinib monotherapy|
|Cisplatin (100) with concurrent RT|35804144|Cisplatin and RT|
|PRIZM+ Zanubrutinib monotherapy (Trial)|42542412|Zanubrutinib monotherapy|
|FOLFIRINOX (metastatic)|35804771|FOLFIRINOX|
|Vinorelbine (oral) Cisplatin|35804260|Cisplatin and Vinorelbine (CVb)|
|Azacitidine (support)|35803465|Azacitidine monotherapy|
|Paclitaxel weekly premedication (support)|35804205|Paclitaxel monotherapy, weekly|
|Carboplatin Pembrolizumab Pemetrexed (CrCl)|35806403|Carboplatin, Pemetrexed, Pembrolizumab|
|Temozolomide with concurrent RT (patients 65 years and over)|35803687|Temozolomide and RT, then Temozolomide|
|CA059-001 CC-95251 Azacitidine (Trial)|35803465|Azacitidine monotherapy|
|Lanreotide Depot|35806580|Lanreotide Depot/Autogel monotherapy|
|Cisplatin Etoposide with concurrent RT (NSCLC)|37557397|Cisplatin and Etoposide (EP) and RT|
|Cyclophosphamide oral +/- Prednisolone (Sarcoma)|35803428|Cyclophosphamide and Prednisolone|
|FEC (75/500)|35804212|FEC|
|Cisplatin (50) RT|35804144|Cisplatin and RT|
|Niraparib|35806485|Niraparib monotherapy|
|Pemetrexed Carboplatin (CrCl)|35806172|Carboplatin and Pemetrexed|
|Sotorasib|905771|Sotorasib monotherapy|
|Vemurafenib|35804101|Vemurafenib monotherapy|
|ARCADIAN Vinorelbine Cisplatin with RT (Trial)|35805351|Cisplatin, Vinorelbine, RT|
|Fedratinib|35101952|Fedratinib monotherapy|
|MVAC accelerated|35804146|MVAC|
|Gemcitabine|35804135|Gemcitabine monotherapy|
|Cisplatin (50) with concurrent RT|35804144|Cisplatin and RT|
|Abiraterone|35806848|Abiraterone monotherapy|
|CHOP-14 bolus|35803591|CHOP-14|
|Gemcitabine Capecitabine (pancreas)|35804557|Capecitabine and Gemcitabine|
|Mogamulizumab|35804815|Mogamulizumab monotherapy|
|FEC (100) Docetaxel (75) Pertuzumab Trastuzumab IV (adjuvant use only)|37560136|FEC-THP (Docetaxel) (trastuzumab-dttb)|
|Ribociclib (aromatase inhibitor)|35804288|Letrozole and Ribociclib|
|EC Docetaxel Pertuzumab Trastuzumab IV (adjuvant)|37560133|EC-TH (Docetaxel) (trastuzumab-dttb)|
|R-BAC-500|35804616|R-BAC|
|Venetoclax Azacitidine (suitable for standard intensive induction DA)|35803466|Azacitidine and Venetoclax|
|Dalteparin prophylaxis|35807097|Dalteparin monotherapy|
|Midostaurin maintenance|35803513|Midostaurin monotherapy|
|Ivosidenib|35803517|Ivosidenib monotherapy|
|Lomustine|35805719|Lomustine monotherapy|
|Atezolizumab|35804138|Atezolizumab monotherapy|
|Olaparib|35804269|Olaparib monotherapy|
|Liposomal doxorubicin Carboplatin (CrCl)|35805245|Carboplatin and Pegylated liposomal doxorubicin|
|ABVD (3 cycles)|35805802|ABVD|
|Osimertinib|35804394|Osimertinib monotherapy|
|Gemcitabine with concurrent RT (bladder)|35804152|Gemcitabine and RT|
|Asciminib|1524898|Asciminib monotherapy|
|Crizotinib|35806424|Crizotinib monotherapy|
|Daratumumab|35806063|Daratumumab monotherapy|
|Alectinib|35804390|Alectinib monotherapy|
|Glofitamab monotherapy (including Obinutuzumab pre-treatment) (EAMS)|37557451|Glofitamab monotherapy|
|Nilotinib|35804079|Nilotinib monotherapy|
|Fludarabine Melphalan Alemtuzumab (30 late) RIC|35803629|Fludarabine, Melphalan, Alemtuzumab|
|EV-302 Arm A Enfortumab vedotin Pembrolizumab (Trial)|37557435|Enfortumab vedotin and Pembrolizumab|
|Olaparib TABLETS|35804269|Olaparib monotherapy|
|Trastuzumab Cisplatin Capecitabine (GOJ)|35805363|Capecitabine and Cisplatin (CX) and Trastuzumab|
|Inotuzumab ozogamicin cycle 2 onwards achieved CR|35804064|Inotuzumab ozogamicin monotherapy|
|Trametinib|35806139|Trametinib monotherapy|
|AVENuE AVD|35805804|AVD|
|EMA/CO (germ cell)|42542356|EMA/CO|
|Tivozanib|905825|Tivozanib monotherapy|
|Busulfan single dose (oral)|35804638|Busulfan monotherapy|
|MK-6482-013 Belzutifan (MK-6482) 200mg (Trial)|905631|Belzutifan monotherapy|
|Apalutamide (support)|35806850|Apalutamide monotherapy|
|Eribulin (compassionate use)|35804265|Eribulin monotherapy|
|Zoledronic acid 4 weekly|35806301|Zoledronic acid therapy|
|Atezolizumab Carboplatin Etoposide (CrCl)|35806941|Carboplatin and Etoposide (CE) and Atezolizumab|
|Carboplatin Pembrolizumab Pemetrexed without pemetrexed maintenance (CrCl)|35806403|Carboplatin, Pemetrexed, Pembrolizumab|
|M18-803 Ibrutinib Venetoclax (Trial)|35806097|Ibrutinib and Venetoclax|
|Trastuzumab deruxtecan (Enhertu)|42542261|Trastuzumab deruxtecan monotherapy|
|Abemaciclib (aromatase inhibitor)|35804280|Abemaciclib and Anastrozole|
|R-Lenalidomide|35804591|Lenalidomide and Rituximab (R2)|
|Cisplatin Pembrolizumab Pemetrexed daypt|35806412|Cisplatin, Pemetrexed, Pembrolizumab|
|Brigatinib|35806423|Brigatinib monotherapy|
|Trastuzumab emtansine (Kadcyla)|35805230|Trastuzumab emtansine monotherapy|
|MK-6482-013 Belzutifan (MK-6482) 120mg (Trial)|905631|Belzutifan monotherapy|
|Carboplatin Paclitaxel Pembrolizumab (CrCl)|35806415|Carboplatin and Paclitaxel (CP) and Pembrolizumab|
|Cisplatin RT (100 H&N) Daypt|35804144|Cisplatin and RT|
|FOLFIRINOX modified (adjuvant)|35807526|FOLFIRINOX/modified FOLFIRINOX +/- Chemoradiation|
|Cisplatin (40) with concurrent RT (head and neck)|35804144|Cisplatin and RT|
|Abemaciclib (aromatase inhibitor) (metastatic)|35804280|Abemaciclib and Anastrozole|
|Busulfan Fludarabine ATG RIC (Allograft)|35803623|Fludarabine, Busulfan, ATG|
|Durvalumab Gemcitabine Cisplatin (cholangiocarcinoma) (compassionate use)|1524839|Cisplatin and Gemcitabine (GC) and Durvalumab|
|Zoledronic acid 3 weekly|35806301|Zoledronic acid therapy|
|Pembrolizumab Pemetrexed Carboplatin (CrCl)|35806403|Carboplatin, Pemetrexed, Pembrolizumab|
|Cyclophosphamide Fludarabine TBI RIC (Haploidentical)|35803627|Fludarabine, Cyclophosphamide, TBI for dUCB or haploidentical transplant|
|Paclitaxel Carboplatin (EDTA)|35803572|Carboplatin and Paclitaxel (CP)|
|Azacitidine (SC)|35803465|Azacitidine monotherapy|
|Paclitaxel Carboplatin (CrCl)|35803572|Carboplatin and Paclitaxel (CP)|
|Fludarabine Melphalan Alemtuzumab (60) RIC (MUD transplant)|35803629|Fludarabine, Melphalan, Alemtuzumab|
|Trastuzumab emtansine (Kadcyla) (compassionate use)|35805230|Trastuzumab emtansine monotherapy|
|Ifosfamide high dose|35804542|Ifosfamide monotherapy|
|Ruxolitinib support|35803508|Ruxolitinib monotherapy|
|Paclitaxel Carboplatin (CrCl) 7 day with RT|35805350|Carboplatin and Paclitaxel (CP) and RT|
|Cisplatin Etoposide (neuroendocrine)|35805329|Cisplatin and Etoposide (EP)|
|Fedratinib (support)|35101952|Fedratinib monotherapy|
|Pembrolizumab Carboplatin Paclitaxel (CrCl)|35806415|Carboplatin and Paclitaxel (CP) and Pembrolizumab|
|Cladribine (Litak) (SC) Rituximab (hairy cell leukaemia)|35805757|Cladribine and Rituximab|
|Pembrolizumab Pemetrexed Carboplatin without pemetrexed maintenance (CrCl)|35806403|Carboplatin, Pemetrexed, Pembrolizumab|
|CNIS793B12201 Arm 3 Gemcitabine Nab-Paclitaxel (Trial)|35804567|Gemcitabine and nab-Paclitaxel|
|Cisplatin Pemetrexed Daypt|35806173|Cisplatin and Pemetrexed|
|Selpercatinib|912062|Selpercatinib monotherapy|
|Dabrafenib|35804434|Dabrafenib monotherapy|
|Cemiplimab|35804822|Cemiplimab monotherapy|
|Denosumab|35804178|Denosumab monotherapy|
|Carboplatin Etoposide (EDTA) (sarcoma)|35806400|Carboplatin and Etoposide (CE)|
|Chlorambucil (days 1 to 7)|35804622|Chlorambucil monotherapy|
|Bosutinib (compassionate use)|35804082|Bosutinib monotherapy|
|Avapritinib (compassionate use)|42542281|Avapritinib monotherapy|
|Paclitaxel (80) (days 1, 8 and 15)|35804205|Paclitaxel monotherapy, weekly|
|STELLAR CHOP-R (Trial)|35805028|R-CHOP|
|Fludarabine Melphalan Alemtuzumab (90) RIC (MUD transplant)|35803629|Fludarabine, Melphalan, Alemtuzumab|
|Cisplatin Etoposide (oral)|35805329|Cisplatin and Etoposide (EP)|
|DREAMM-3 Pomalidomide Dexamethasone (Trial)|42542407|Pomalidomide and Dexamethasone (Pd)|
|Fludarabine Melphalan Alemtuzumab (60 late) RIC (off study PRO-DLI)|35803629|Fludarabine, Melphalan, Alemtuzumab|
|Zoledronic acid 6 weekly|35806301|Zoledronic acid therapy|
|Polatuzumab Rituximab Cyclophosphamide Doxorubicin Prednisolone (PR-CHP)|37559679|Pola-R-CHP (rituximab-rixa)|
|TOPAZ-1 Durvalumab / placebo monotherapy (Trial)|35804164|Durvalumab monotherapy|
|Lenalidomide (MDS)|35803596|Lenalidomide monotherapy|
|Osimertinib (support)|35804394|Osimertinib monotherapy|
|Atezolizumab Bevacizumab (EAMS)|35806408|Atezolizumab and Bevacizumab|
|Zoledronic acid 4 weekly (support)|35806301|Zoledronic acid therapy|
|Vismodegib (compassionate use)|35804821|Vismodegib monotherapy|
|rEECur Topotecan Cyclophosphamide (off study)|35805453|Cyclophosphamide and Topotecan|
|Vismodegib|35804821|Vismodegib monotherapy|
|Romiplostim|35805922|Romiplostim monotherapy|
|Vinorelbine (oral)|35804241|Vinorelbine monotherapy|
|Cytarabine high dose|35803435|High-dose Cytarabine monotherapy (HiDAC)|
|PARTNER Carboplatin Paclitaxel (Trial)|35803572|Carboplatin and Paclitaxel (CP)|
|Cisplatin (40 weekly) RT (cervix)|35804144|Cisplatin and RT|
|Pacritinib (compassionate use)|1525214|Pacritinib monotherapy|
|Cladribine (Litak) (SC)|35803546|Cladribine monotherapy|
|Carboplatin Fluorouracil (CrCl)|35805773|Carboplatin and Fluorouracil|
|Carboplatin Paclitaxel (NSCLC) (CrCl)|35803572|Carboplatin and Paclitaxel (CP)|
|Niraparib (relapsed)|35806485|Niraparib monotherapy|
|Temozolomide 75 + RT (patients 65 years and over)|35803686|Temozolomide and RT|
|Fluorouracil (96hr CIV) infusor with RT|35804534|Fluorouracil and RT|
|Carboplatin Etoposide (EDTA) (Oral etoposide days 2+3)|35806400|Carboplatin and Etoposide (CE)|
|Busulfan (oral) (single dose) (support)|35804638|Busulfan monotherapy|
|Vinorelbine oral|35804241|Vinorelbine monotherapy|
|Ruxolitinib (compassionate use)|35803508|Ruxolitinib monotherapy|
|VAC (off study)|35806910|VAC|
|Cediranib (compassionate use)|905688|Cediranib monotherapy|
|Capecitabine (1000mg/m2)|35804227|Capecitabine monotherapy|
|MoTD Fludarabine Busulfan experimental group 2 (Trial)|35803612|Busulfan and Fludarabine|
|Mitomycin Capecitabine 42 day|35804560|Capecitabine and Mitomycin|
|DA-EPOCH-R (etopsode phosphate)|35804378|DA-R-EPOCH|
|Pexidartinib (compassionate use)|1524984|Pexidartinib monotherapy|
|Trastuzumab emtansine (Kadcyla) (adjuvant)|35805230|Trastuzumab emtansine monotherapy|
|Liposomal doxorubicin Carboplatin (CrCl) (ovarian)|35805245|Carboplatin and Pegylated liposomal doxorubicin|
|Daratumumab (cycle 1 standard rate then rapid rate subsequent cycles)|35806063|Daratumumab monotherapy|
|Zoledronic acid (lymphoma bone protection) (support)|35806301|Zoledronic acid therapy|
|AVENuE ABVD (Trial)|35805802|ABVD|
|Methylprednisolone 1mg/kg|35807042|Methylprednisolone monotherapy|
|Cisplatin RT (40 H&N) weekly daypt|35804144|Cisplatin and RT|
|Zoledronic acid 3 weekly (support)|35806301|Zoledronic acid therapy|
|Zoledronic acid 6 monthly|35806301|Zoledronic acid therapy|
|DA|35807524|DA 3+10|
|Plerixafor + GCSF priming|35101641|Plerixafor and G-CSF|
|Ipilimumab Nivolumab (mesothelioma) (compassionate use)|35806133|Ipilimumab-Nivolumab|
|Busulfan Fludarabine ATG RIC (AML/MDS) (Allograft)|35803623|Fludarabine, Busulfan, ATG|
|ABVD (ABVD 2 cycles AVD 4 cycles)|35805802|ABVD|
|Dalteparin therapeutic solid tumours|35807097|Dalteparin monotherapy|
|R-Lenalidomide (IV rituximab cycle 1 then SC)|37558891|Lenalidomide and Rituximab-abbs (R2)|
|Cisplatin (40 weekly) RT (cervix) daypt|35804144|Cisplatin and RT|
|Pirtobrutinib (Compassionate Use)|37556847|Pirtobrutinib monotherapy|
|FLAIR Ibrutinib monotherapy (NCRN Trial)|35804581|Ibrutinib monotherapy|
|Ipilimumab Nivolumab (renal cell)|35806133|Ipilimumab-Nivolumab|
|Talazoparib (Compassionate use)|35804270|Talazoparib monotherapy|
|Crizanlizumab (support)|42542402|Crizanlizumab monotherapy|
|Cisplatin (40) with concurrent RT (cervix)|35804144|Cisplatin and RT|
|Dexamethasone daily|35804388|Dexamethasone monotherapy|
|Avelumab (EAMS)|35804159|Avelumab monotherapy|
|Trastuzumab emtansine (Kadcyla) (metastatic)|35805230|Trastuzumab emtansine monotherapy|
|UPSTREAM (EORTC1559) Niraparib (Trial)|35806485|Niraparib monotherapy|
|MoTD Fludarabine Busulfan MF experimental group 2 (Trial)|35803612|Busulfan and Fludarabine|
|Pertuzumab Trastuzumab IV (metastatic)|35804314|Pertuzumab and Trastuzumab|
|Pertuzumab Trastuzumab IV (neoadjuvant)|35804314|Pertuzumab and Trastuzumab|
|Olaparib tablets (Managed access programme)|35804269|Olaparib monotherapy|
|Docetaxel (75) (prostate)|35804162|Docetaxel monotherapy|
|Bevacizumab 15mg/Kg|35803688|Bevacizumab monotherapy|
|Mini-BEAM (5 day) modified|35805837|Mini-BEAM|
|Lenvatinib Pembrolizumab 42 day|42542382|Lenvatinib and Pembrolizumab|
|Venetoclax|35804617|Venetoclax monotherapy|
|ASTX727-02 Decitabine then ASTX727 (Trial)|912034|Decitabine and cedazuridine monotherapy|
|Cyclophosphamide (oral)|35803690|Cyclophosphamide monotherapy|
|Ifosfamide infusional (inpatient)|35804542|Ifosfamide monotherapy|
|STAMPEDE J HT + Abiraterone + Enzalutamide (NCRN Trial)|911935|Abiraterone and Enzalutamide|
|daNIS-3 NIS793 mFOLFOX Bevacizumab (Trial)|37558784|mFOLFOX6-B (bevacizumab-onbe)|
|MaxiCHOP Cytarabine HD Rituximab|37559740|maxi-R-CHOP/R-HiDAC (rituximab-rixa)|
|MoTD Fludarabine Busulfan experimental group 2 (off study)|35803612|Busulfan and Fludarabine|
|XL184-311 Cabozantinib / Placebo (Trial)|35805797|Cabozantinib monotherapy|
|Pertuzumab Trastuzumab IV (adjuvant)|35804314|Pertuzumab and Trastuzumab|
|AZA-MDS-003 (NCRN 525) Azacitidine tablets / placebo (Trial)|35803465|Azacitidine monotherapy|
|Plerixafor + GCSF priming (protocol A)|35101641|Plerixafor and G-CSF|
|Cetuximab Irinotecan Modified DeGramont|35804798|Irinotecan and Cetuximab|
|AZA-MDS-003 (NCRN 525) Azacitidine tablets / placebo (NCRN trial)|35803465|Azacitidine monotherapy|
|Busulfan (oral)|35804638|Busulfan monotherapy|
|Larotrectinib (weeks 1 to 12 only)|35806364|Larotrectinib monotherapy|
|Niraparib (first line maintenance)|35806485|Niraparib monotherapy|
|Irinotecan weekly|35803692|Irinotecan monotherapy|
|Zoledronic acid 6 monthly (support)|35806301|Zoledronic acid therapy|
|PLATO Mitomycin Capecitabine 23 days (ACT3 or ACT4) (NCRN Trial)|35803671|Capecitabine, Mitomycin, RT|
|INTERIM Dabrafenib Trametinib intermittent (Trial)|35804100|Dabrafenib and Trametinib|
|Dexamethasone 40mg 1 day|35804388|Dexamethasone monotherapy|
|Cetuximab Irinotecan Modified de Gramont|35804798|Irinotecan and Cetuximab|
|Bexarotene induction|35804812|Bexarotene monotherapy|
|MoTD Fludarabine Busulfan MF control group 1 (Trial)|35803612|Busulfan and Fludarabine|
|Regorafenib (GIST)|35804569|Regorafenib monotherapy|
|Melphalan high dose (Autograft)|35806058|Melphalan, then auto HSCT|
|Etoposide PO (support)|35803691|Etoposide monotherapy|
|Rituximab single agent (standard)|35803432|Rituximab monotherapy|
|Cetuximab weekly|35804795|Cetuximab monotherapy|
|IMbrave251 (MO42541) Atezolizumab Sorafenib (Trial)|37558188|Sorafenib and Atezolizumab|
|Carboplatin AUC 5 CrCl (support)|35804537|Carboplatin monotherapy|
|ALL-RIC Fludarabine Melphalan Alemtuzumab (MUD) (Trial)|35803629|Fludarabine, Melphalan, Alemtuzumab|
|Etoposide oral flexible dosing (support)|35803691|Etoposide monotherapy|
|Lenvatinib Pembrolizumab 42 day (endometrial)|42542382|Lenvatinib and Pembrolizumab|
|Lenalidomide maintenance (post autologous stem cell transplant)|35803596|Lenalidomide monotherapy|
|Etoposide oral (myeloid)|35803691|Etoposide monotherapy|
|ENRICH Ibrutinib Rituximab (28 day) (NCRN Trial)|35804612|Ibrutinib and Rituximab|
|Vinorelbine (60-80) oral|35804241|Vinorelbine monotherapy|
|213400 (ZEAL-1L) Pembrolizumab Niraparib / placebo (Trial)|37556844|Niraparib and Pembrolizumab|
|Prednisolone reducing dose|35803431|Prednisolone monotherapy|
|Imatinib ALL|35804083|Imatinib monotherapy|
|Rituximab maintenance 1st remission only (2 monthly)|37561187|RT-PEPC; Maintenance (rituximab-rixi)|
|Bortezomib weekly|35804520|Bortezomib monotherapy|
|PETReA Rituximab SC maintenance (Trial)|37561187|RT-PEPC; Maintenance (rituximab-rixi)|
|UKALL 2011 Regimen C Augmented BFM consolidation (off study)|35804055|Augmented BFM consolidation|
|MoTD Fludarabine Melphalan experimental group 2 (Trial)|35803628|Fludarabine and Melphalan|
|Daratumumab (Named patient supply)|35806063|Daratumumab monotherapy|
|Rituximab IV maintenance 1st remission only (2 monthly)|37561187|RT-PEPC; Maintenance (rituximab-rixi)|
|SYD985.002 (TULIP) Lapatinib Capecitabine (Trial)|35804311|Capecitabine and Lapatinib|
|Rituximab Gemcitabine Dexamethasone Cisplatin (R-GDP) (Daypatient)|37559705|R-GDP (rituximab-rixa)|
|Rituximab Gemcitabine Dexamethasone Cisplatin (R-GDP) (daypatient)|37559705|R-GDP (rituximab-rixa)|
|Cetuximab Cisplatin Fluorouracil (100 H&N) infusor|35805359|Cisplatin and Fluorouracil (CF) and Cetuximab|
|Dactinomycin (2 weekly) (germ cell)|35805247|Dactinomycin monotherapy|
|Irinotecan Oxaliplatin Modified DeGramont (FOLFOXIRI)|35807526|FOLFIRINOX/modified FOLFIRINOX +/- Chemoradiation|
|Rituximab SC maintenance 2nd remission only (3 monthly)|37561187|RT-PEPC; Maintenance (rituximab-rixi)|
|Doxorubicin infusion (support)|35804134|Doxorubicin monotherapy|
|Cyclophosphamide IV infusion (support)|35803690|Cyclophosphamide monotherapy|
|Mitotane (Lysodren) (support)|35803585|Mitotane monotherapy|
|Trametinib (compassionate use)|35806139|Trametinib monotherapy|
|Nelarabine (aged 25 years and under) (support)|35806983|Nelarabine monotherapy|
|Epirubicin weekly|35804228|Epirubicin monotherapy|
|Enzalutamide (after at least 3 months of stable dose enzalutamide treatment)|35804322|Enzalutamide monotherapy|
|Pemetrexed maintenance|35804168|Pemetrexed monotherapy|
|CO43805 Mosunetuzumab cycle 1 (Trial)|37557146|Mosunetuzumab monotherapy|
|CABL001A2301 Bosutinib arm (Trial)|35804082|Bosutinib monotherapy|
|AVENuE Avelumab (Trial)|35804159|Avelumab monotherapy|
|Doxycycline (amyloidosis)|35806103|Doxycycline monotherapy|
|DICE Arm 1 Paclitaxel (Trial)|35804166|Paclitaxel monotherapy|
|Paclitaxel Cisplatin (ovarian) daypt|35804527|Cisplatin and Paclitaxel (TP)|
|Bexarotene maintenance|35804812|Bexarotene monotherapy|
|Mitomycin Fluorouracil + RT infusor daypt|35803673|Fluorouracil, Mitomycin, RT|
|Cytarabine HD 3g/m2|35804417|Methotrexate-Cytarabine|
|MoTD Fludarabine Melphalan control group 1 (Trial)|35803628|Fludarabine and Melphalan|
|ENRICH Ibrutinib Rituximab (21 day) (NCRN Trial)|35804612|Ibrutinib and Rituximab|
|Durvalumab 28 day|35804164|Durvalumab monotherapy|
|Fulvestrant intramuscular injection (support)|35804284|Fulvestrant monotherapy|
|Carboplatin AUC 1.5 CrCl (support)|35804537|Carboplatin monotherapy|
|Daratumumab SC (cycles 1 to 6) then IV (cycle 7 onwards) (compassionate use)|35806063|Daratumumab monotherapy|
|Melphalan Prednisolone Thalidomide (MPT)|35806286|MPT|
|Paclitaxel 7 day Carboplatin (CrCl) (ovarian)|35803572|Carboplatin and Paclitaxel (CP)|
|Paclitaxel Carboplatin 21 day (EDTA)|35803572|Carboplatin and Paclitaxel (CP)|
|Radium-223 (Xofigo)|35806862|Radium-223 monotherapy|
|Bevacizumab 7.5mg/kg|35803688|Bevacizumab monotherapy|
|CANC3947 TITAN post trial Apalutamide (off study compassionate use)|35806850|Apalutamide monotherapy|
|Radium 223 (Xofigo)|35806862|Radium-223 monotherapy|
|FEDORA (RG_21-109) Fedratinib pre-treatment (Trial)|35101952|Fedratinib monotherapy|
|Durvalumab 14 day|35804164|Durvalumab monotherapy|
|Osimertinib (adjuvant) (ORBIS)|35804394|Osimertinib monotherapy|
|PATHOS Cisplatin RT (NCRN Trial)|35804144|Cisplatin and RT|
|Blinatumomab 3 days then 4 days (starting on Monday, Tuesday or Friday) <45kg|35804056|Blinatumomab monotherapy|
|Etoposide oral (sarcoma)|35803691|Etoposide monotherapy|
|MoTD Fludarabine Melphalan experimental group 2 (off study)|35803628|Fludarabine and Melphalan|
|ENRICH R-CHOP (NCRN Trial)|35805028|R-CHOP|
|Siltuximab (Castleman disease)|35804521|Siltuximab monotherapy|
|Bevacizumab (compassionate use)|35804319|Bevacizumab-containing therapy|
|ENRICH Ibrutinib Rituximab (28 day) (Trial)|35804612|Ibrutinib and Rituximab|
|Blinatumomab 4 days then 3 days (starting Monday, Thursday or Friday) ambulate|35804056|Blinatumomab monotherapy|
|Phesgo (Pertuzumab with Trastuzumab) SC (adjuvant)|37560284|Pertuzumab and Trastuzumab-herw|
|Vincristine additional (support)|35807043|Vincristine monotherapy|
|Ibrutinib (Waldenstrom?s macroglobulinaemia)|35804581|Ibrutinib monotherapy|
|Bevacizumab Paclitaxel Carboplatin 21 day (CrCl) (cervix)|35806401|Carboplatin and Paclitaxel (CP) and Bevacizumab|
|Obinutuzumab maintenance|35804583|Obinutuzumab monotherapy|
|Blinatumomab 3 days then 4 days (starting Monday, Tuesday or Friday) ambulate|35804056|Blinatumomab monotherapy|
|Blinatumomab 4 days then 3 days (starting on Monday, Thursday or Friday)|35804056|Blinatumomab monotherapy|
|IMMU-132-13 Paclitaxel (Trial)|35804166|Paclitaxel monotherapy|
|TRITON3 CO-338-063 Rucaparib (NCRN Trial)|35806484|Rucaparib monotherapy|
|Larotrectinib (week 13 onwards)|35806364|Larotrectinib monotherapy|
|Blinatumomab 3 days then 4 days (starting on Monday, Tuesday or Friday)|35804056|Blinatumomab monotherapy|
|PRIME-RT Arm B (Trial)|1524906|Arms B (Nelarabine Arms)|
|CLEE011O12301C (NATALEE) Ribociclib arm (Trial)|35804283|Anastrozole, Goserelin, Ribociclib|
|REMoDL-A R-CHOP cycle 1 (Trial)|35805028|R-CHOP|
|FLAIR Ibrutinib Rituximab (NCRN Trial)|35804612|Ibrutinib and Rituximab|
|MVAC accelerated daypt|35804146|MVAC|
|BP42675 Obinutuzumab pre-treatment (Trial)|35804583|Obinutuzumab monotherapy|
|FEDR-MF-002 (FREEDOM 2) Fedratinib (Trial)|35101952|Fedratinib monotherapy|
|EZ|37560722|E-X|
|Abemaciclib (endocrine therapy) (adjuvant)|35804281|Abemaciclib and Letrozole|
|Methotrexate high dose Cytarabine high dose (primary CNS lymphoma)|35804417|Methotrexate-Cytarabine|
|rEECur Ifosfamide (off study)|35804542|Ifosfamide monotherapy|
|CHOP-21 bolus|35805093|CHOP-BCG|
|Rituximab single agent (weekly) (support)|35803432|Rituximab monotherapy|
|GCSF filgrastim priming 0.5MU/Kg/day|37558834|COG AAML1421 protocol (filgrastim-aafi)|
|NEPTUNES Ipilimumab Nivolumab (cohort 2) (Trial)|35806134|Nivolumab-Ipilimumab|
|INITIUM (UV1-202) Ipilimumab Nivolumab (Trial)|35804435|Ipilimumab and Nivolumab|
|MAGNETISMM-5 (C1071005) Arm A Elranatamab (Trial)|37557432|Elranatamab monotherapy|
|Bevacizumab 7.5mg/kg 3 weekly (support)|35803688|Bevacizumab monotherapy|
|Bevacizumab maintenance|35803688|Bevacizumab monotherapy|
|GCSF filgrastim priming 1.0MU/Kg/day|37558834|COG AAML1421 protocol (filgrastim-aafi)|
|Atezolizumab 28 day|35804138|Atezolizumab monotherapy|
|Acalabrutinib (CLL) (compassionate use)|35804606|Acalabrutinib monotherapy|
|OASIS II Arm A Ibrutinib Rituximab (Trial)|35804612|Ibrutinib and Rituximab|
|54767414MMY3003 (NCRN 2993) Daratumumab monotherapy (NCRN Trial)|35806063|Daratumumab monotherapy|
|Atezolizumab 21 day|35804138|Atezolizumab monotherapy|
|Panitumumab Irinotecan Modified de Gramont|35804800|Panitumumab monotherapy|
|UKALL 60+ Arm C Phase 1 Induction (Off Study)|37561927|No induction therapy|
|Intrathecal Cytarabine|35803502|Cytarabine and Thioguanine|
|Carboplatin AUC 5 EDTA (support)|37558432|Carboplatin, Pemetrexed, Bevacizumab-awwb|
|PLATFORM Arm A4 Rucaparib maintenance (NCRN Trial)|35806484|Rucaparib monotherapy|
|Bevacizumab 7.5mg/kg (support)|35804319|Bevacizumab-containing therapy|
|RADAR Arm A ABVD (Trial)|35805802|ABVD|
|Ibrutinib Rituximab (SC) maintenance (Mantle cell lymphoma) 1st line|35804612|Ibrutinib and Rituximab|
|EPIK-B3 (CBYL719H12301) A/B2 Paclitaxel albumin-bound Alpelisib/placebo (Trial)|35804167|Paclitaxel, nanoparticle albumin-bound monotherapy|
|Trastuzumab SC|37561200|TCHP (Docetaxel, SC Trastuzumab)|
|MUK nine b VRD (SC) consolidation part 2 (Trial)|37557464|International ALL Trial consolidation|
|Add Aspirin Randomised trial treatment (NCRN Trial)|35806655|Aspirin monotherapy|
|BREAKWATER (C4221015) Arm C mFOLFOX6 (Trial)|1524843|COG AAML1031 arm A (low-risk)|
|TRIZELL rAd-IFN-MM-301 Celecoxib (Trial)|37557395|Celecoxib, Erlotinib, Methotrexate, Nivolumab|
|RELATIVITY098 (CA224098) BMS-986213 or Nivolumab (Trial)|37557193|Cabozantinib, Ipilimumab, Nivolumab|
|Calcium folinate 350mg|37557474|mFOLFIRINOX (no folinic acid)|
|Denosumab (metastases) 4 weekly (28 day cycle)|35804205|Paclitaxel monotherapy, weekly|
|REMoDL-A R-CHOP cycles 2-6 (Trial)|35806080|R-CHOP/R-DHAP|
|Enzalutamide (metastatic hormone relapsed) (support)|911935|Abiraterone and Enzalutamide|
|Venetoclax continuation (support)|35804617|Venetoclax monotherapy|
|LOXO-BTK-20019 Arm A LOXO-305 (Pirtobrutinib) (Trial)|37556847|Pirtobrutinib monotherapy|
|CEeDD Cohort 3 Cetuximab Irinotecan Modified de Gramont (Trial)|35804798|Irinotecan and Cetuximab|
|Obinutuzumab Glofitamab (compassionate use)|35804583|Obinutuzumab monotherapy|
|Cisplatin Fluorouracil (100 H&N) infusor Daypt|35803672|Cisplatin and Fluorouracil (CF) and RT|
|Carboplatin AUC 6 (CrCl)|37556795|Carboplatin and Doxorubicin|
|ICON 9 Olaparib Arm 2 (Trial)|35804269|Olaparib monotherapy|
|Cisplatin Fluorouracil (80 H&N) infusor Daypt|35803672|Cisplatin and Fluorouracil (CF) and RT|
|Daratumumab SC Bortezomib Dexamethasone (neuropathy) (cycles 1-8 only) (21 day)|35806321|Bortezomib, Thalidomide, Dexamethasone, Panobinostat|
|Cisplatin (50) (cervix)|35102030|Carboplatin and Cisplatin|
|ALL Consolidation cycle 1 (25-60 years)|1525160|No consolidation|
|SYD985.002 (TULIP) SYD985 arm (Trial)|1524843|COG AAML1031 arm A (low-risk)|
|GO40311 BTRC4017A Trastuzumab one step fractionation (Trial)|35804222|Trastuzumab monotherapy|
|Denosumab (metastases)|35804178|Denosumab monotherapy|
|ATRA (Tretinoin) (Emergency use)|35803549|Arsenic trioxide and ATRA|
|D5330C00004 Module 2 Ceralasertib Olaparib (Trial)|912013|Olaparib and Bevacizumab|
|Prednisolone 1mg/kg 7 days|35803431|Prednisolone monotherapy|
|GCSF filgrastim (variable number of days up to 10)|37558834|COG AAML1421 protocol (filgrastim-aafi)|
|Cyclophosphamide IV bolus for use with DTPACE or VTDPACE only (support)|35804235|Dose-dense Cyclophosphamide monotherapy|
|PK 2013 01 VDC/IE (Trial)|35805450|VDC/IE|
|EV-302 Arm B Gemcitabine Cisplatin (Trial)|35806427|Cisplatin and Gemcitabine/Erlotinib|
|Trastuzumab SC 21 day|35804222|Trastuzumab monotherapy|
|CHARIOT Cisplatin Capecitabine stage A2 or B induction (Trial)|35805336|Capecitabine, Cisplatin, RT|
|Nivolumab 28 day|35803677|Nivolumab monotherapy|
|RP3-301 Nivolumab cohorts 3 and 4 (Trial)|35803677|Nivolumab monotherapy|
|CVP bolus (patients under 70 years)|35804599|CVP|
|CONTRAST BI-1607 Trastuzumab (Trial)|35804222|Trastuzumab monotherapy|
|Etoposide IV split bags support|35803691|Etoposide monotherapy|
|Pembrolizumab 400mg (relapsed/metastatic)|35803678|Pembrolizumab monotherapy|
|SCIB1-002 Nivolumab Ipilimumab SCIB1 (Trial)|35806134|Nivolumab-Ipilimumab|
|AML19 CPX-351 (NCRN Trial)|35803473|CPX-351 monotherapy|
|ALL-RIC Intrathecal Methotrexate (Trial)|35804095|Methotrexate monotherapy|
|Prednisolone 1mg/kg 14 days|35803431|Prednisolone monotherapy|
|BEP 5 day metastatic|35803570|BEP|
|Nivolumab 28 day (compassionate use)|35803677|Nivolumab monotherapy|
|Nivolumab 14 day (compassionate use)|35803677|Nivolumab monotherapy|
|GCSF filgrastim 7 days|37558834|COG AAML1421 protocol (filgrastim-aafi)|
|BEP 3 day metastatic|35803570|BEP|
|GCSF filgrastim priming|37558834|COG AAML1421 protocol (filgrastim-aafi)|
|ENRICH Ibrutinib maintenance (Trial)|35804581|Ibrutinib monotherapy|
|Pembrolizumab 200mg then 400mg (relapsed/metastatic)|35803678|Pembrolizumab monotherapy|
|Pembrolizumab 200mg then 400mg (adjuvant)|35803678|Pembrolizumab monotherapy|
|GCSF filgrastim 3 days|37558834|COG AAML1421 protocol (filgrastim-aafi)|
|Pembrolizumab 2mg/kg (metastatic)|35803678|Pembrolizumab monotherapy|
|GO40311 Trastuzumab cycle 1 day -1 (support) (Trial)|35804222|Trastuzumab monotherapy|
|Trastuzumab (8/6) (adjuvant) 21 day (support)|35804222|Trastuzumab monotherapy|
|Atezolizumab 28 day (adjuvant)|35804138|Atezolizumab monotherapy|
|INITIUM (UV1-202) Nivolumab maintenance (Trial)|35803677|Nivolumab monotherapy|
|Prednisolone 1mg/kg 21 days|35803431|Prednisolone monotherapy|
|GCSF filgrastim 5 days|37558834|COG AAML1421 protocol (filgrastim-aafi)|
|Venetoclax titration continuation (support)|35804617|Venetoclax monotherapy|
|Imatinib 400-600 (GIST/sarcomas)|35804083|Imatinib monotherapy|
|Trastuzumab (8/6) (metastatic) 21 day|35804222|Trastuzumab monotherapy|
|Pembrolizumab 400mg (adjuvant)|35803678|Pembrolizumab monotherapy|
|Add Aspirin Run in (NCRN Trial)|35806655|Aspirin monotherapy|
|MAP (APMM)|35806469|MAP|
|Methotrexate high dose (high grade NHL CNS prophylaxis)|35804095|Methotrexate monotherapy|
|Cardamon maintenance (Carfilzomib) (NCRN Trial)|35806280|Carfilzomib monotherapy|
|CVP bolus (patients over 70 years)|35804599|CVP|
|Euro Ewing 2012 VDC/IE (off study)|35805450|VDC/IE|
|Pembrolizumab 21 day then 42 day (adjuvant)|35803678|Pembrolizumab monotherapy|
|CACZ885T2301 Canakinumab/Placebo (Trial)|35803590|Placebo|
|MITHRIDATE (RG_16-148) Pegylated Interferon Alfa-2a (Trial)|35805377|Peginterferon alfa-2a monotherapy|
|54767414MMY3008 (CANC-4387) Daratumumab subequent therarapy (NCRN Trial)|1524917|Dara-Rd (SC daratumumab)|
|Nivolumab 14 day (relapsed/metastatic)|35803677|Nivolumab monotherapy|
|Trastuzumab (8/6) (metastatic) 21 day (support)|35804222|Trastuzumab monotherapy|
|Bevacizumab 14 day (neurofibromatosis 2)|35803688|Bevacizumab monotherapy|
|Cetuximab skin toxicity|35804795|Cetuximab monotherapy|
|ACE-WM-001 ACP-196 (commercial study)|911939|ACP|
|Nivolumab 14 day (adjuvant)|35803677|Nivolumab monotherapy|
|Pembrolizumab 200mg (adjuvant)|35803678|Pembrolizumab monotherapy|
|RP2-001-18 Nivolumab RP2 (Trial)|35803677|Nivolumab monotherapy|
|Pembrolizumab 42 day (adjuvant)|35803678|Pembrolizumab monotherapy|
|Hydroxycarbamide support|35805376|Hydroxyurea monotherapy|
|OptiMATe Arm B MATRIx (Trial)|35804413|MATRix|
|OptiMATe Arm B R-MTX pre-phase (Trial)|37559371|MT-R (rituximab-pvvr)|
|NEPTUNES Nivolumab monotherapy (Trial)|35803677|Nivolumab monotherapy|
|LUD2015-005 Cohort C-FLOT (NCRN Trial)|35805341|FLOT|
|Venetoclax extra doses for cycles delayed after titration completed (support)|35804617|Venetoclax monotherapy|
|Pembrolizumab 42 day (relapsed/metastatic)|35803678|Pembrolizumab monotherapy|
|Nivolumab 28 day (adjuvant)|35803677|Nivolumab monotherapy|
|Nivolumab 14 day (EAMS)|35803677|Nivolumab monotherapy|
|Nivolumab 28 day (metastatic)|35803677|Nivolumab monotherapy|
|OptiMATe Arm A MATRIx (Trial)|35804413|MATRix|
|Pembrolizumab 21 day (adjuvant)|35803678|Pembrolizumab monotherapy|
|Bevacizumab 21 day (neurofibromatosis 2)|35803688|Bevacizumab monotherapy|
|Mouth and bowel support|35803468|Best supportive care|
|Ibrutinib (CLL) >3years progression free interval (no comorbidities) cycles 1-3|35804581|Ibrutinib monotherapy|
|BEP 3 day adjuvant|35807017|Accelerated BEP|
|Brightline-1 Doxorubicin (Trial)|35804134|Doxorubicin monotherapy|
|ALL Consolidation cycle 3 days 1-28 (25-60 years)|37557464|International ALL Trial consolidation|
|BEP 3 day adjuvant (BEP 111)|35807017|Accelerated BEP|
|DTPACE (cyclophosphamide bolus)|35806327|DTPACE|
|Busulfan Fludarabine ATG RIC (myelofibrosis) (Allograft)|35803623|Fludarabine, Busulfan, ATG|
|Niraparib (Expanded access programme)|35806485|Niraparib monotherapy|
|rEECur Topotecan Cyclophosphamide (TC) (NCRN Trial)|35805453|Cyclophosphamide and Topotecan|
|Docetaxel Carboplatin Trastuzumab (TCH)||No mapping|
|Ixazomib Lenalidomide Dexamethasone||No mapping|
|Pertuzumab Trastuzumab Docetaxel||No mapping|
|Carfilzomib Lenalidomide Dexamethasone||No mapping|
|Epirubicin Oxaliplatin Fluorouracil||No mapping|
|Pembrolizumab Paclitaxel albumin-bound||No mapping|
|Paclitaxel weekly Trastuzumab||No mapping|
|Mitomycin Capecitabine with concurrent RT||No mapping|
|Carfilzomib Pomalidomide Dexamethasone||No mapping|
|Gemcitabine Paclitaxel albumin bound||No mapping|
|Bevacizumab (7.5mg/kg) Paclitaxel Carboplatin (CrCl)||No mapping|
|Docetaxel Carboplatin Trastuzumab (TCH) CrCl||No mapping|
|Temozolomide||No mapping|
|Oxaliplatin Raltitrexed||No mapping|
|Afatinib||No mapping|
|Apalutamide||No mapping|
|Letrozole||No mapping|
|Paclitaxel albumin bound (support)||No mapping|
|Atezolizumab Paclitaxel albumin-bound||No mapping|
|Bevacizumab (15mg/kg) Paclitaxel Carboplatin (CrCl)||No mapping|
|Carboplatin Etoposide Ifosfamide (CarboPEI)||No mapping|
|FOLFOXIRI||No mapping|
|Carboplatin Capecitabine + RT (CrCl)||No mapping|
|Vinorelbine PO (60) Carboplatin AUC5 (CrCl)||No mapping|
|Raltitrexed Oxaliplatin||No mapping|
|Docetaxel||No mapping|
|FLAG-IDA Venetoclax||No mapping|
|Dacarbazine (melanoma)||No mapping|
|Exemestane||No mapping|
|Sunitinib||No mapping|
|EC Docetaxel Pertuzumab Trastuzumab (adjuvant)||No mapping|
|EC Paclitaxel (dose dense)||No mapping|
|Vinorelbine PO (60-80) Cisplatin Daypt||No mapping|
|Palbociclib (aromatase inhibitor)||No mapping|
|Liposomal doxorubicin||No mapping|
|Ponatinib||No mapping|
|Paclitaxel (weekly for 3 weeks then 1 week off) Trastuzumab||No mapping|
|Cabozantinib||No mapping|
|Irinotecan||No mapping|
|Dacarbazine (sarcoma)||No mapping|
|Nivolumab Oxaliplatin Capecitabine||No mapping|
|EC||No mapping|
|Pembrolizumab Oxaliplatin Capecitabine||No mapping|
|Gemcitabine Paclitaxel albumin bound (support)||No mapping|
|Oxaliplatin Capecitabine (OX)||No mapping|
|Olaparib (compassionate use)||No mapping|
|PARTNER Olaparib (Trial)||No mapping|
|Eribulin||No mapping|
|Daratumumab Pomalidomide Dexamethasone||No mapping|
|Bortezomib Thalidomide Dexamethasone (VTD) (28 day cycle)||No mapping|
|Cyclophosphamide Lenalidomide Dexamethasone (weekly cyclophosphamide)||No mapping|
|Cisplatin (60) Etoposide (120) (SCLC) Daypt||No mapping|
|Isatuximab Pomalidomide Dexamethasone||No mapping|
|Zanubrutinib||No mapping|
|Olaparib (relapsed/metastatic)||No mapping|
|Methotrexate Mercaptopurine Indometacin||No mapping|
|Carboplatin Vinorelbine oral with concurrent RT (CrCl)||No mapping|
|Ifosfamide (3g) Doxorubicin (30mg) (sarcoma)||No mapping|
|Bortezomib Thalidomide Dexamethasone (VTD) (21 day cycle)||No mapping|
|Paclitaxel (80) Carboplatin (AUC 2) (CrCl) weekly||No mapping|
|Acalabrutinib||No mapping|
|Bevacizumab Pembrolizumab Carboplatin Paclitaxel (CrCl)||No mapping|
|Pertuzumab Trastuzumab Docetaxel (metastatic)||No mapping|
|Ixazomib Lenalidomide Dexamethasone (named patient supply)||No mapping|
|Doxorubicin Cisplatin Cyclophosphamide (CAP)||No mapping|
|Epirubicin Oxaliplatin Capecitabine (EOX)||No mapping|
|Cisplatin (75) Etoposide (100) (SCLC) Daypt||No mapping|
|Quizartinib (compassionate use)||No mapping|
|Omeprazole||No mapping|
|Erlotinib||No mapping|
|IE/VC||No mapping|
|AMM cycles 5-6 MAP (off study)||No mapping|
|CCS1477-02 CCS1477-MB 4 days on 3 days off (Trial)||No mapping|
|75276617ALE1001 JNJ75276617 tablets (Trial)||No mapping|
|FLAMSA-BU >=60 years (off study)||No mapping|
|Ciprofloxacin for prophylaxis||No mapping|
|ACELARATE Acelarin infusion bag (NCRN Trial)||No mapping|
|Lorazepam||No mapping|
|PlasmaMATCH Cohort E (NCRN Trial)||No mapping|
|Pamidronate 30 28 day (support)||No mapping|
|RomiCar (NCRN Trial)||No mapping|
|Oral cryotherapy||No mapping|
|CLARITY (NCRN Trial)||No mapping|
|ST101-101 ST101 expansion (Trial)||No mapping|
|Atropine sulphate||No mapping|
|Metoclopramide 14 day||No mapping|
|PIANO (NCRN Trial)||No mapping|
|RADAR Arm B A2VD (Trial)||No mapping|
|Colestyramine||No mapping|
|RP2-001-18 re-initiation of RP2 (Trial)||No mapping|
|Micafungin||No mapping|
|Fosaprepitant IV||No mapping|
|AIDA||No mapping|
|APMM 2 cycles (MAP) (off study)||No mapping|
|Loperamide||No mapping|
|RP2-001-18 re-initiation of RP2 (support) (Trial)||No mapping|
|LOGIC2; Run in (early phase trial)||No mapping|
|OVM-200-100 OVM-200 (Trial)||No mapping|
|Metoclopramide 28 day||No mapping|
|LATITUDE (NCRN 433) Open label extension phase (NCRN Trial)||No mapping|
|Hydroxycarbamide initiation||No mapping|
|Magnesium support||No mapping|
|MOTION Vimseltinib (Trial)||No mapping|
|ROMAZA cohorts -2, -1, 1 and 2 (NCRN Trial)||No mapping|
|Anaphylaxis treatment||No mapping|
|NX-5948-301 NX-5948 (Trial)||No mapping|
|RPL-001-16 re-initiation (support) (Trial)||No mapping|
|Metoclopramide 7 day||No mapping|
|RXC004/0001 run in (Trial)||No mapping|
|Loratadine||No mapping|
|Cetirizine 28 days||No mapping|
|Cetirizine 7 days||No mapping|
|ATTAINMENT Module 1 MDX-124 (Trial)||No mapping|
|Ondansetron 12 days prn||No mapping|
|Movicol||No mapping|
|KEYNOTE-867 (MK3475-867) (Trial)||No mapping|
|Metoclopramide 3 day||No mapping|
|High emetic risk ondanestron weekly cisplatin||No mapping|
|Pyridoxine 50mg||No mapping|
|Famotidine||No mapping|
|Euro Ewing 2012 IE/VC (off study)||No mapping|
|Aciclovir prophylaxis 200mg tds||No mapping|
|Entecavir||No mapping|
|Hydroxycarbamide||No mapping|
|Nystatin||No mapping|
|Palonosetron IV||No mapping|
|KEYNOTE-867 (MK3475-867-00) (Trial)||No mapping|
|Calcium carbonate Vitamin D||No mapping|
|Ibandronic acid||No mapping|
|Aciclovir-prophylaxis||No mapping|
|Ondansetron metoclopramide 1 day||No mapping|
|Ondansetron metoclopramide||No mapping|
|Furosemide PO 1 day||No mapping|
|Famotidine premed||No mapping|
|Ondansetron metoclopramide days 1, 8 and 15||No mapping|
|ALL Maintenance (25-60 years)||No mapping|
|RP3-301 RP3 (support) (Trial)||No mapping|
|Levofloxacin prophylaxis 28 days||No mapping|
|CEDAR Enadenotucirev loading (Trial)||No mapping|
|Dexrazoxane (cardiotoxicity)||No mapping|
|ANIMATE (CA209-445) (Trial)||No mapping|
|Low emetic risk prochlorperazine||No mapping|
|Sodium chloride 0.9% IV ambulatory infusor||No mapping|
|Epaderm Emollient||No mapping|
|Fluconazole prophylaxis||No mapping|
|Ondansetron metoclopramide 5 days||No mapping|
|PICC line pack||No mapping|
|MUK nine b RD (SC) maintenance (Trial)||No mapping|
|Cyclizine||No mapping|
|COMICE (Trial)||No mapping|
|High emetic rsk ondansetron metoclopramide days 1, 8 and 15||No mapping|
|High emetic risk ondansetron metoclopramide 5 days||No mapping|
|Lorazepam daily||No mapping|
|Olanzapine||No mapping|
|Rasburicase||No mapping|
|Ondansetron day 1 oral premedication||No mapping|
|Moderate emetic risk ondansetron metoclopramide 5 days||No mapping|
|Moderate emetic risk ondansetron 1 day||No mapping|
|Moderate emetic risk ondansetron liquids 1 day||No mapping|
|Moderate emetic risk ondansetron 3.5 days||No mapping|
|Moderate emetic risk ondansetron 5 days||No mapping|
|Darbepoeitin weekly||No mapping|
|Moderate emetic risk ondansetron 1.5 days||No mapping|
|High emetic risk ondansetron 5 days||No mapping|
|High emetic risk ondansetron 2 days||No mapping|
|High emetic risk ondansetron 1.5 days||No mapping|
|High emetic risk ondansetron 1 day||No mapping|
|Moderate emetic risk ondansetron 1 day weekly||No mapping|
|Paracetamol soluble||No mapping|
|Moderate emetic risk ondansetron metoclopramide 1 day||No mapping|
|Moderate emetic risk ondansetron metoclopramide days 1, 8 and 15||No mapping|
|High emetic risk ondansetron 3 days||No mapping|
|Low emetic risk domperidone||No mapping|
|High emetic risk ondansetron metoclopramide 1 day||No mapping|
|Colesevelam||No mapping|
|Moderate emetic risk ondansetron liquids||No mapping|
|High emetic risk ondansetron liquids||No mapping|
|High emetic risk ondansetron days 1, 8 and 15||No mapping|
|AMADEUS (Trial)||No mapping|
|Diprobase||No mapping|
|Mesna IV||No mapping|
|Pembrolizumab 21 day then 42 day (relapsed/metastatic)||No mapping|
|ACCEPT Phase 1 cohort 2 and phase 2 cycles 1-6 (Trial)||No mapping|
|NUTIDE 302 NUFIRI Q1W (Trial)||No mapping|
|Liposomal amphotericin B (Ambisome) prophylaxis||No mapping|
|ONC001 Part A1 cohort 4 (4 weekly) (Trial)||No mapping|
|DREAMM-9 Belantamab mafodontin VRd (every cycle) (Trial)||No mapping|
|UKALL 2011 Regimen B1/C1 maintenance (males) (off study)||No mapping|
|CC-92480-MM-001 21/28 OD schedule (Trial)||No mapping|
|DREAMM-9 Belantamab mafodontin Rd maintenance (every cycle) (Trial)||No mapping|
|Difflam||No mapping|
|RP2-001-18 RP2 (Trial)||No mapping|
|Posaconazole prophylaxis||No mapping|
|Sodium chloride 0.9% IV (Venetoclax hydration)||No mapping|
|Sodium chloride 0.9% 500ml IV infusion||No mapping|
|75276617ALE1001 JNJ75276617 capsules (Trial)||No mapping|
|Ferinject 1000mg IVI||No mapping|
|Paracetamol oral||No mapping|
|Hydroxycarbamide (alternate day dosing)||No mapping|
|Stem cells||No mapping|
|Methylene blue||No mapping|
|TIMEPOINT (MNA-3521-012) MTL-CEBPA Pembrolizumab (Trial)||No mapping|
|CANC3947 TITAN Open label (NCRN Trial)||No mapping|
|TALAPRO-2 (C3441021) part 2 (Trial)||No mapping|
|Pamidronate 30 28 day||No mapping|
|PEACOCC (Trial)||No mapping|
|ARCADIAN Atovaquone (Trial)||No mapping|
|Calcium levofolinate 175mg||No mapping|
|EORTC-HGUS 62113-55115 (Trial)||No mapping|
|IMP-MEL IMM60 (Trial)||No mapping|
|Sodium chloride IV infusion||No mapping|
|WINGMEN Xentuzumab (Trial)||No mapping|
|OCTOVA Arm C (NCRN Trial)||No mapping|
|ALL Intensification / CNS prophylaxis (25-60 years)||No mapping|
|ALL Consolidation cycle 3 days 29-42 (25-60 years)||No mapping|
|1480-0001 (IV STING) BI 1703880 Ezabenlimab (Trial)||No mapping|
|Pembrolizumab 21 day (relapsed/metastatic)||No mapping|
|STP938-101 STP938 (Trial)||No mapping|
|Codeine Phosphate po||No mapping|
|IMG-7289-CTP-102 IMG-7289 (Trial)||No mapping|
|Potassium chloride 20mmol IV||No mapping|
|Rituximab weekly (ITP)||No mapping|
|Lamivudine||No mapping|
|Levomepromazine||No mapping|
|DREAMM-9 Belantamab mafodontin Rd maintenance (every 3rd cycle) (Trial)||No mapping|
|RMS 2005 IVADo cycles 1-3 (off study)||No mapping|
|Chlorphenamine 7 days||No mapping|
|ACE-CL-001 ACP-196 Cohort 2b (NCRN Trial)||No mapping|
|Darbepoeitin 3 weekly||No mapping|
|MOTION Vismeltinib (Trial)||No mapping|
|Azithromycin prophylaxis (250mg) 3 x week 28 day||No mapping|
|Atropine sulphate (5 days)||No mapping|
|Isoniazid||No mapping|
|Ranitidine premed IV||No mapping|
|Azithromycin prophylaxis (250mg) 3 x week 21 day||No mapping|
|Pentamidine prophylaxis IV||No mapping|
|EP 166/50 daypt||No mapping|
|BEP 3 day metastatic (NSCGT) daypt||No mapping|
|Magnesium sulphate 8mmol IV||No mapping|
|75276617ALE1001 JNJ75276617 (Trial)||No mapping|
|M16-191 Transform-1 (Trial)||No mapping|
|DREAMM-9 Belantamab mafodontin VRd (every 3rd cycle from cycle 4) (Trial)||No mapping|
|CCS1477-02 CCS1477 3 days on 4 days off (Trial)||No mapping|
|Cimetidine premed||No mapping|
|CC-92480-MM-001 20/28 schedule (Trial)||No mapping|
|Metoclopramide 21 day||No mapping|
|EORTC-HGUS 62113-55115 (open label) (Trial)||No mapping|
|ACE-CL-001 ACP-196 Cohort 8 (NCRN Trial)||No mapping|
|NUTIDE 302 NUFOX Q1W (Trial)||No mapping|
|RP3-301 RP3 (Trial)||No mapping|
|RATinG Lenzilumab (stage 1) (support) (Trial)||No mapping|
|CA290-841 (CONFIRM) (Trial)||No mapping|
|Magnesium sulphate 20mmol IV||No mapping|
|Ipi-Glio Arm A (Trial)||No mapping|
|Ondansetron for oral Vinorelbine days 1, 8 and 15||No mapping|
|CC-4047-MM-013 (Commercial trial)||No mapping|
|LUD2015-005 Post surgery Cohorts C and D (NCRN Trial)||No mapping|
|BEP 5 day metastatic (NSCGT) daypt||No mapping|
|RMS 2005 IVADo IVA cycles 4-9 (off study)||No mapping|
|Anaphylaxis prophylaxis||No mapping|
|STAMPEDE K SoC & Metformin (NCRN Trial)||No mapping|
|CEeDD SonoTran particles cohorts 1, 2B and 3B (Trial)||No mapping|
|D9571C00001 AZD7789 (Trial)||No mapping|
|Allopurinol for prevention of tumour lysis syndrome||No mapping|
|Aciclovir prophylaxis 200mg bd||No mapping|
|NX-1607-101 NX-1607 (Trial)||No mapping|
|UKALL 2011 Regimen B Standard BFM consolidation (off study)||No mapping|
|UKALL 60+ Arm A Maintenance (off study)||No mapping|
|MATTERHORN (D910GC00001) Durvalumab/placebo FLOT (Trial)||No mapping|
|MATRIX NLMT Arm J (Ceralasertib Durvalumab) (Trial)||No mapping|
|M16-109 (REFINE) Navitoclax monotherapy (Trial)||No mapping|
|Capecitabine (1250) adjuvant||No mapping|
|Rituximab 100mg dose (support)||No mapping|
|MonarchE Arm A Abemaciclib + SoC endocrine (NCRN Trial)||No mapping|
|KY1044-CT01 Atezolizumab KY1044 24mg infusion bag (Trial)||No mapping|
|Dexrazoxane||No mapping|
|STAR-221 Arm A Domvanalimab Zimberelimab FOLFOX (Trial)||No mapping|
|Capecitabine Phesgo SC (metastatic)||No mapping|
|CRUKD/22/002 HMBD-001 Arm 1 monotherapy (Trial)||No mapping|
|Daratumumab SC (c1-3) then IV (c4-8) Bortezomib Dexam (neuropathy 21d) (compas)||No mapping|
|UKALL 60+ Arm D Consolidation 1 (off study)||No mapping|
|VDTPACE (cyclophosphamide bolus)||No mapping|
|AML19 Cytarabine high dose (NCRN Trial)||No mapping|
|GCSF filgrastim||No mapping|
|NG-641-03 (NEBULA) NG-641 Nivolumab (Trial)||No mapping|
|RPL-001-16 Phase 1 expansion or Phase 2 Nivolumab & RP1 (Trial)||No mapping|
|Bendamustine 90-R (NHL)||No mapping|
|ALL Consolidation cycle 2 (25-60 years)||No mapping|
|5F9005 Magrolimab Azacitidine AML/MDS expansion (Trial)||No mapping|
|STAMPEDE G HT + Abiraterone (NCRN Trial)||No mapping|
|Co-trimoxazole 480mg 3xweekly||No mapping|
|D933LC00001 (BEGONIA) Arm 1 (Trial)||No mapping|
|PRIME-RT Arm A (Trial)||No mapping|
|Cisplatin 21 day (ovarian) daypt||No mapping|
|CT7001-001 Module 1 Cycle 1 onwards (Trial)||No mapping|
|Imatinib CML (support)||No mapping|
|ADCT-402-201 (Trial)||No mapping|
|ACE-536-MDS-002 (COMMANDS) Epoetin alfa (Trial)||No mapping|
|ACE-536-MF-001 (Trial)||No mapping|
|KRT-232-101 28 day cycle (Trial)||No mapping|
|MEDI4736-NHL-001 Arm B (NHL) (NCRN Trial)||No mapping|
|D933LC00001 (BEGONIA) Arm 2 (Trial)||No mapping|
|GS-US-546-5920 Cohort 2 Mag+MEC (Trial)||No mapping|
|Aprepitant with dexamethasone (day 1 on ward)||No mapping|
|UKALL 60+ Arm C Maintenance (Off Study)||No mapping|
|PETReA Obintuzumab maintenance (Trial)||No mapping|
|Ibrutinib (CLL) (support)||No mapping|
|ALL Consolidation cycle 4 (25-60 years)||No mapping|
|STAR-221 Arm B Nivolumab FOLFOX (Trial)||No mapping|
|Pembrolizumab 200mg (relapsed/metastatic)||No mapping|
|CA017-078 Nivolumab BMS-986205/Placebo adjuvant (Trial)||No mapping|
|Aprepitant with dexamethasone (day 1 at home)||No mapping|
|D933LC00001 (BEGONIA) Arm 6 (Trial)||No mapping|
|Methotrexate 50 (germ cell)||No mapping|
|Lansoprazole||No mapping|
|RADAR (Myeloma XV) RCyBorD induction (Trial)||No mapping|
|CEDAR Capecitabine RT Enadenotucirev maintenance (Trial)||No mapping|
|PEMBROWM Pembrolizumab Rituximab (Trial)||No mapping|
|ONC001 Part A or Part A1 cohorts 1 and 2 (2 weekly) (Trial)||No mapping|
|RP3-301 RP3 Nivolumab cohorts 1 and 5 (Trial)||No mapping|
|MUK nine b VRDd consolidation part 1 (Trial)||No mapping|
|UKALL 2011 Regimen B3/C3 maintenance (males) (NCRN Trial)||No mapping|
|MITHRIDATE (RG_16-148) Ruxolitinib (Trial)||No mapping|
|Cisplatin hydration (cisplatin dose >=61mg/m2)||No mapping|
|ONC001 Part A1 cohort 3 (3 weekly) (Trial)||No mapping|
|CCS1477-02 CCS1477-MB 4 days on 3 days off bd dosing (without azoles) (Trial)||No mapping|
|ACCEPT Phase 1 cohort 2 and phase 2 cycles 7-8 (Trial)||No mapping|
|D8231C00001 AZD4573 cycle 1 (Trial)||No mapping|
|CC-90009-AML-001 Gen 2 days 1-10 (Trial)||No mapping|
|Ibrutinib (Mantle cell lymphoma) 2nd line||No mapping|
|Atezolizumab 21 day (relapsed/metastatic)||No mapping|
|GCSF pegfilgrastim||No mapping|
|RAMPART Arm C (Trial)||No mapping|
|GS-US-546-5920 Cohort 1 Mag+Ven+Aza (Trial)||No mapping|
|D933LC00001 (BEGONIA) Arm 5 (Trial)||No mapping|
|RMS 2005 Vinorelbine Cyclophosphamide maintenance (Off  Study)||No mapping|
|Fludarabine Melphalan RIC (Allograft)||No mapping|
|Denosumab (metastases) 6 weekly||No mapping|
|Rituximab IV 375mg/m2||No mapping|
|EC Docetaxel Phesgo SC (neoadjuvant node negative / unknown)||No mapping|
|Bendamustine 90-R firstline (CLL)||No mapping|
|Carboplatin desensitisation (CrCl) (support)||No mapping|
|Aprepitant without dexamethasone (day 1 on ward)||No mapping|
|Aspirin 75||No mapping|
|AML19 FLAG-Ida course 2 standard risk (NCRN Trial)||No mapping|
|Nivolumab Oxaliplatin Modified de Gramont (EAMS)||No mapping|
|LOXO-BTK-20022 Arm B Venetoclax Rituximab cycle 1 (Trial)||No mapping|
|Majic Ruxolitinib PV (NCRN Trial)||No mapping|
|TRIZELL rAd-IFN-MM-301 rAd-IFN Celecoxib (Trial)||No mapping|
|Add Aspirin randomised trial treatment (NCRN Trial)||No mapping|
|Doxorubicin (urgent use)||No mapping|
|UKALL 60+ Arm A Consolidation (off study)||No mapping|
|ENHANCE (5F9009) Magrolimab / placebo Azacitidine (Trial)||No mapping|
|Carboplatin desensitisation (CrCl)||No mapping|
|LOXO-BTK-20022 Arm B Venetoclax Rituximab cycles 2-25 (Trial)||No mapping|
|Trastuzumab IV||No mapping|
|Cetuximab Oxaliplatin Modified de Gramont||No mapping|
|ACTICCA-1 Gemcitabine Cisplatin (Trial)||No mapping|
|UKALL 60+ Arm D Phase 1 and 2 Induction (off study)||No mapping|
|Melphalan high dose (Autograft) (renal impairment)||No mapping|
|Carboplatin AUC 5 (EDTA)||No mapping|
|ISIS-702843-CS4 Cohort A (Trial)||No mapping|
|INITIUM (UV1-202) UV1 Ipilimumab Nivolumab (Trial)||No mapping|
|FGCL-4592-082 Roxadustat / placebo (Trial)||No mapping|
|CABL001J12301 Arm 2 Imatinib (Trial)||No mapping|
|Ibrutinib Rituximab (IV cycle 1 then SC c2-6) (Mantle cell lymphoma) 1st line||No mapping|
|PCYC-1128-CA Cohort 5 Ibrutinib (NCRN Trial)||No mapping|
|PROSPER Enzalutamide open label (commercial trial)||No mapping|
|PRISM (ACE-LY-111) Arm 1 Acalabrutinib AZD9150 (Trial)||No mapping|
|R3767-ONC-1613 REGN3767 and REGN2810 combination (Trial)||No mapping|
|1426-0001 Arm B BI 138746 BI 754091 (Trial)||No mapping|
|Intrathecal Methotrexate||No mapping|
|Belantamab mafodontin (GSK2857916) (compassionate use)||No mapping|
|NUTIDE 302 Bevacizumab (support) (Trial)||No mapping|
|RiVa Arm B (Trial)||No mapping|
|Nivolumab 14 day||No mapping|
|NUTIDE 701 NUC-7738 Pembrolizumab (Trial)||No mapping|
|Cisplatin hydration (cisplatin dose =<40mg/m2)||No mapping|
|CA017-078 Gemcitabine Cisplatin Nivolumab BMS-986205/Placebo (Trial)||No mapping|
|FLAIR Fludarabine Cyclophosphamide Rituximab (NCRN Trial)||No mapping|
|Phesgo (Pertuzumab with Trastuzumab) SC (metastatic)||No mapping|
|PRO-DLI (Fludarabine Melphalan Alemtuzumab) (Trial)||No mapping|
|Carboplatin AUC 7 (CrCl)||No mapping|
|Denosumab (metastases) 4 weekly (84 day cycle)||No mapping|
|BEACOPDac escalated||No mapping|
|UKALL 2011 Regimen C Capizzi interim maintenance (off study)||No mapping|
|Docetaxel (100) (adjuvant) 21 day||No mapping|
|Irinotecan Modified DeGramont (NET)||No mapping|
|ATRA (Tretinoin) (emergency use continuation) support||No mapping|
|D8231C00001 AZD4573 cycle 2 onwards (Trial)||No mapping|
|CDK-002-101 (Trial)||No mapping|
|Constellation (0610-02) Arms 2 and 3 CPI-610 Ruxolitinib (Trial)||No mapping|
|CRUKD/11/001;Vandeta+Selumetinib(od)dose escalation_C2onwards (EarlyPhaseTrial)||No mapping|
|Erythropoietin zeta weekly||No mapping|
|Carboplatin 21 day (CrCl) breast||No mapping|
|Imatinib (GIST)||No mapping|
|Nivolumab Oxaliplatin Modified de Gramont||No mapping|
|CO41942 Mosun+Len Mosunetuzumab Lenalidomide cycles 2-12 (Trial)||No mapping|
|CA017-078 Gemcitabine Cisplatin (Trial)||No mapping|
|Cetuximab 2 weekly combination (support)||No mapping|
|ENRICH Ibrutinib additional (NCRN Trial)||No mapping|
|Irinotecan Capecitabine 21 day||No mapping|
|UPSTREAM (EORTC1559) Durvalumab Monalizumab (Trial)||No mapping|
|Dexamethasone pre docetaxel 16mg IV 1 day||No mapping|
|Denosumab (metastases) 4 weekly||No mapping|
|LOXO-BTK-20019 Arm B Ibrutinib (Trial)||No mapping|
|Constellation (0610-02) Arm 4 CPI-0610 monotherapy (Trial)||No mapping|
|CA224048 Relatlimab Nivolumab Ipilimumab (Trial)||No mapping|
|Phesgo (Pertuzumab with Trastuzumab) SC (adjuvant) (support)||No mapping|
|REMoDL-A Acalabrutinib R-CHOP cycles 2-6 (Trial)||No mapping|
|PROMise PLX2853 Ruxolitinib (Trial)||No mapping|
|Dexamethasone pre docetaxel 20mg IV 1 day||No mapping|
|FLA-IDA||No mapping|
|LOXO-BTK-20022 Arm A Pirtobrutinib Venetoclax Rituximab (Trial)||No mapping|
|CNIS793B12301 (dANIS-2) NIS793/placebo Gemcitabine Nab-paclitaxel (Trial)||No mapping|
|5F9003 Hu5F9-G4 + R-GemOx cycle 1 (Trial)||No mapping|
|Ibrutinib (lymphoma) (compassionate use)||No mapping|
|UKALL 2011 Regimen C Delayed intensification (off study)||No mapping|
|CABL001E2201 Imatinib arm (Trial)||No mapping|
|daNIS-3 NIS793 FOLFIRI Bevacizumab (Trial)||No mapping|
|EC Docetaxel Phesgo SC (neoadjuvant node positive)||No mapping|
|Imatinib ALL (support)||No mapping|
|TRIZELL rAd-IFN-MM-301 Gemcitabine (Trial)||No mapping|
|CC-4047-MM-007 (CANC4276) Bortezomib Dexamethasone Pomalidomide (NCRN Trial)||No mapping|
|Carboplatin 21 day (EDTA)||No mapping|
|Daratumumab Bortezomib Dexamethasone (cycle 9 onwards) (28 day) rapid rate||No mapping|
|Dexamethasone pre/post docetaxel 8mg po weekly prostate||No mapping|
|Cyclophosphamide priming prior to PBSC harvest||No mapping|
|Irinotecan Oxaliplatin Modified de Gramont modified (neoadjuvant)||No mapping|
|APHRODITE Capecitabine (Trial)||No mapping|
|FEDORA (RG_21-109) Fedratinib Ropeginterferon alfa-2b (Trial)||No mapping|
|Panitumumab Irinotecan Modified DeGramont||No mapping|
|Irinotecan Modified de Gramont||No mapping|
|Enzalutamide (metastatic hormone relapsed)||No mapping|
|Methotrexate weekly (Large granular cell leukaemia)||No mapping|
|Imatinib 400-600||No mapping|
|STELLAR CHOP-R Acalabrutinib (Trial)||No mapping|
|Carboplatin VTDPACE (support)||No mapping|
|Daratumumab Bortezomib Dexamethasone (neuropathy) (cycles 1 to 8 only) (21 day)||No mapping|
|CO41942 Mosun+Len Mosunetuzumab SC Lenalidomide cycle 1 (Trial)||No mapping|
|CO41942 Mosun+Len Mosunetuzumab SC Lenalidomide cycles 2-12 (Trial)||No mapping|
|Denosumab (metastases) 12 weekly||No mapping|
|Bortezomib (TTP)||No mapping|
|Dexamethasone pre/post docetaxel 20mg IV 8mg po 3 day (RBFT)||No mapping|
|CT7001-001 Module 2 part A (Trial)||No mapping|
|Mesna for cyclophosphamide 750||No mapping|
|ALL Phase 1 Induction (25-60 years)||No mapping|
|Rituximab SC maintenance 2nd remission only (3 monthly) (Lymphoma)||No mapping|
|UKALL 60+ Arm A Phase 1 and 2 induction (off study)||No mapping|
|Trastuzumab SC (support)||No mapping|
|EXCALIBER-RRMM (CC-220-MM-002) Arm A (Trial)||No mapping|
|Aprepitant without dexamethasone (day 1 at home)||No mapping|
|InterAACT Carboplatin Paclitaxel (CrCl) (off study)||No mapping|
|Daratumumab Bortezomib Dexamethasone (neuropathy) (cycles 1 to 8 only) 21 rapid||No mapping|
|Ondansetron temozolomide 5 day||No mapping|
|KY1044-CT01 Atezolizumab KY1044 (Trial)||No mapping|
|PETReA Rituximab SC Lenalidomide maintenance (Trial)||No mapping|
|Mitotane (Lysodren)||No mapping|
|Irinotecan Oxaliplatin Modified de Gramont (metastatic)||No mapping|
|ALL Phase 2 Induction (25-60 years)||No mapping|
|ACTICCA-1 Capecitabine (Trial)||No mapping|
|Carboplatin AUC 10 (CrCl)||No mapping|
|Carboplatin AUC 5 (CrCl)||No mapping|
|Rituximab SC maintenance 1st remission only (2 monthly) (Lymphoma)||No mapping|
|CA224048 Relatlimab Nivolumab BMS-986205 (Trial)||No mapping|
|AC (sarcoma)||No mapping|
|Ibrutinib (Waldenstroms macroglobulinaemia)||No mapping|
|Midostaurin (mastocytosis)||No mapping|
|COSI Mini Thiotepa Busulphan Fludarabine ATG (mini TBF) (Trial)||No mapping|
|Capecitabine (1250) metastatic||No mapping|
|Rituximab SC maintenance 1st remission only (2 monthly)||No mapping|
|Ibrutinib (Mantle cell lymphoma)||No mapping|
|Cisplatin Imatinib||No mapping|
|ENRICH Rituximab SC maintenance (Trial)||No mapping|
|Docetaxel (75) (metastatic) 21 day||No mapping|
|SCOPE 2 Capecitabine Cisplatin cycles 2-4 Arms 2 and 4 (NCRN Trial)||No mapping|
|1426-0001 Arm A BI 1387446 (Trial)||No mapping|
|Mitomycin Modified de Gramont||No mapping|
|Idarubicin IV (support)||No mapping|
|RAMPART Arm B (Trial)||No mapping|
|CTD (weekly cyclophosphamide)||No mapping|
|AGI-134.FIM.101 Monotherapy treatment (Trial)||No mapping|
|Panitumumab Oxaliplatin Modified DeGramont||No mapping|
|Omeprazole 5 day||No mapping|
|Carboplatin 21 day (CrCl)||No mapping|
|GRN163LMYF3001  Arm A Imetelstat (Trial)||No mapping|
|ENRICH Ibrutinib Rituximab SC maintenance (Trial)||No mapping|
|NUTIDE 302 Arm 2A NUC-3373 weekly Oxaliplatin (Trial)||No mapping|
|COPELIA Arm 2 Cediranib Paclitaxel (Trial)||No mapping|
|Fludarabine Cyclophosphamide Rituximab CLL (Flu-Cy-R) (Oral)||No mapping|
|Panitumumab Oxaliplatin Modified de Gramont||No mapping|
|VTDPACE (cyclophosphamide bolus)||No mapping|
|Dexamethasone pre/post docetaxel 8mg po 3 day||No mapping|
|ENRICH Ibrutinib Rituximab SC maintenance (NCRN Trial)||No mapping|
|Docetaxel Phesgo SC (metastatic)||No mapping|
|FCiST Streptozocin Cisplatin Fluorouracil (Neuroendocrine) inpt||No mapping|
|Cabozantinib (RCC) (MAP)||No mapping|
|PARTNER AZD6738 Durvalumab (PARTNERING) (Trial)||No mapping|
|ENRICH Rituximab SC maintenance (NCRN Trial)||No mapping|
|Docetaxel Carboplatin Phesgo SC (neoadjuvant node positive) CrCl||No mapping|
|Capecitabine (1250) (biliary tract)||No mapping|
|Etoposide IV (HLH)||No mapping|
|PARTNER FEC100 (Trial)||No mapping|
|RAINBOW Dexamethasone Cyclophosphamide Rituximab (Trial)||No mapping|
|COPELIA Arm 3 Olaparib Cediranib (Trial)||No mapping|
|Imatinib (GIST/sarcomas)||No mapping|
|AG946-C-002 Phase 2a (Trial)||No mapping|
|Temozolomide 150/200 (astrocytoma)||No mapping|
|UKALL 2011 Regimen B Induction standard dexamethasone (off study)||No mapping|
|Obinutuzumab CVP||No mapping|
|CO41942 Mosun+Len Mosunetuzumab Lenalidomide cycle 1 (Trial)||No mapping|
|PCYC-1116-CA; Ibrutinib (commercial trial)||No mapping|
|Ibrutinib (CLL)||No mapping|
|Ibrutinib (Waldenstroms macroglobulinaemia)||No mapping|
|Daratumumab SC Bortezomib Dexamethasone (cycles 1 to 8 only) (21 day)||No mapping|
|Dexamethasone pre/post docetaxel 4mg po 3 day||No mapping|
|Cyclophosphamide Fludarabine TBI FIC (MUD transplant/cord cells)||No mapping|
|NUTIDE 302 Arm 2B NUC-3373 weekly Irinotecan (Trial)||No mapping|
|Daratumumab SC Bortezomib Dexamethasone (cycle 9 onwards) (28 day)||No mapping|
|Constellation (0610-02) Arm 1 CPI-0610 monotherapy (Trial)||No mapping|
|Trastuzumab Oxaliplatin Modified de Gramont||No mapping|
|EC Capecitabine Daypt||No mapping|
|M14-239 Telisotuzumab vedotin (Trial)||No mapping|
|BI 1280.8 Arm A BI 836845 (1000mg) Enzalutamide (Trial)||No mapping|
|Irinotecan Modified DeGramont||No mapping|
|UKALL 2011 Regimen B Delayed intensification (off study)||No mapping|
|CABL001A2001B Asciminib Imatinib arm (Trial)||No mapping|
|Daratumumab Bortezomib Dexamethasone (cycles 1 to 8 only) (21 day) rapid rate||No mapping|
|Bortezomib weekly Cyclophosphamide Dexamethasone (CyBorDex) (Amyloidosis)||No mapping|
|COSI Fludarabine Busulphan 4 (FB4) (Trial)||No mapping|
|Imatinib (sarcoma)||No mapping|
|CAR-T Fludarabine Cyclophosphamide Tisagenlecleucel (NHL)||No mapping|
|POD1UM-303 (InterAACT 2) INCMGA00012 / placebo Paclitaxel Carboplatin (Trial)||No mapping|
|PLATO Mitomycin Capecitabine 28 days (ACT4 or ACT5) (NCRN Trial)||No mapping|
|Capecitabine (1000) breast||No mapping|
|R-CHOP-21 bolus||No mapping|
|PRIMUS 001 Paclitaxel albumin bound Gemcitabine (Trial)||No mapping|
|Chlorambucil-R (continuous)||No mapping|
|Chlorambucil-R (days 1 to 14)||No mapping|
|Methotrexate (50)||No mapping|
|Imatinib (CML)||No mapping|
|CABL001E2201 Asciminib 60mg Imatinib arm (Trial)||No mapping|
|Docetaxel Carboplatin Pertuzumab Trastuzumab IV (adjuvant use only)||No mapping|
|Oxaliplatin Capecitabine 21 day||No mapping|
|ATOMIC-MESO (POLARIS 2015-003) ADI-PEG/Placebo Cisplatin Pemetrexed (Trial)||No mapping|
|Gemtuzumab Daunorubicin Cytarabine induction||No mapping|
|Cyclophosphamide TBI Alemtuzumab (MUD transplant)||No mapping|
|Vyxeos (Daunorubicin / Cytarabine) liposomal consolidation||No mapping|
|CABL001A2301 ABL001 arm (Trial)||No mapping|
|SCOPE 2 Carboplatin (CrCl) Paclitaxel cycles 2-4 Arms 1 and 3 (NCRN Trial)||No mapping|
|UTX-TGR-205 Arm A Ublituximab TGR-1202 (Trial)||No mapping|
|ENRICH Bendamustine-R (Trial)||No mapping|
|Carmustine Thiotepa (High dose)||No mapping|
|CNIS793B12201 Arm 2 NIS793 Gemcitabine Nab-Paclitaxel (Trial)||No mapping|
|Enzalutamide (newly diagnosed metastatic)||No mapping|
|Cetuximab 2 weekly||No mapping|
|Cisplatin (support)||No mapping|
|CNIS793B12201 Arm 1 Spartalizumab NIS793 Gemcitabine Nab-Paclitaxel (Trial)||No mapping|
|SCOPE 2 Carboplatin (CrCl) Paclitaxel cycle 1 All patients (Trial)||No mapping|
|MoTD Fludarabine Melphalan experimental group 3 (Trial)||No mapping|
|MAGNETISMM-5 (C1071005) Arm C Daratumumab Pomalidomide Dexamethasone (Trial)||No mapping|
|Paclitaxel Carboplatin 21 day (CrCl)||No mapping|
|Dexamethasone pre/post docetaxel 20mg IV 8mg po 2 day||No mapping|
|Dexamethasone pre/post docetaxel 20mg IV 8mg po 3 day||No mapping|
|ICON 9 Olaparib Cediranib Arm 1 (Trial)||No mapping|
|Sunitinib (GIST)||No mapping|
|FLAIR Ibrutinib Venetoclax (NCRN Trial)||No mapping|
|Abiraterone Prednisolone (support)||No mapping|
|Oxaliplatin Modified de Gramont||No mapping|
|Abiraterone Prednisolone (after at least 3 months of stable dose abiraterone)||No mapping|
|COSI Fludarabine Busulphan 2 (FB2) (Trial)||No mapping|
|daNIS-3 NIS793 Tislelizumab FOLFIRI Bevacizumab (Trial)||No mapping|
|Epirubicin (20) weekly||No mapping|
|SGN35-032 Brentuximab vedotin Cyclophosphamide Doxorubicin Prednisone (Trial)||No mapping|
|IMGN632-0802 Regimen C AZA+VEN+IMGN632 (Trial)||No mapping|
|Docetaxel (75) (NSCLC)||No mapping|
|Oxaliplatin Modified DeGramont||No mapping|
|SCOPE 2 Capecitabine Cisplatin cycle 1 All patients (NCRN Trial)||No mapping|
|Omeprazole premed||No mapping|
|5F9003 Hu5F9-G4 Rituximab (Trial)||No mapping|
|Capecitabine (2000mg bd) 7/7||No mapping|
|Midostaurin Daunorubicin Cytarabine (cytarabine bolus DA)||No mapping|
|Gemcitabine Dexamethasone Cisplatin (GDP) (Daypatient)||No mapping|
|Docetaxel Carboplatin Phesgo SC (neoadjuvant node negative / unknown) CrCl||No mapping|
|FLAG Venetoclax||No mapping|
|BEAM Alemtuzumab (Allograft)||No mapping|
|CABL001E2201 Asciminib 40mg Imatinib arm (Trial)||No mapping|
|CompARE Arm 5 Cisplatin Durvalumab (NCRN Trial)||No mapping|
|Capecitabine (1000)||No mapping|
|Olaparib capsules (400mg bd)||No mapping|
|IMC-F106C-101 IMC-F106C Paclitaxel albumin bound (Trial)||No mapping|
|Gemcitabine Dexamethasone Cisplatin (GDP)||No mapping|
|ICE modified||No mapping|
|CAR-T Fludarabine Cyclophosphamide Axicabtagene ciloleucel||No mapping|
|EC Paclitaxel Carboplatin (CrCl)||No mapping|
|Gemcitabine (1000) Carboplatin (CrCl) (breast)||No mapping|
|Gemcitabine (pancreas)||No mapping|
|5F9005 Hu5F9-G4 Azacitidine evaluation (Trial)||No mapping|
|Cytarabine HD Rituximab||No mapping|
|Mitotane||No mapping|
|COSI Fludarabine Busulphan 2 (FB4) (off study)||No mapping|
|Sunitinib (pNET)||No mapping|
|OASIS II Arm B Ibrutinib Venetoclax Rituximab (Trial)||No mapping|
|MoTD Fludarabine Busulfan MF experimental group 3 (Trial)||No mapping|
|POMB/ACE||No mapping|
|R-VP||No mapping|
|Dasatinib (chronic phase CML)||No mapping|
|Docetaxel Pertuzumab Trastuzumab IV (metastatic)||No mapping|
|Paclitaxel albumin-bound Phesgo SC (metastatic)||No mapping|
|Daunorubicin liposomal Cytarabine liposomal (Vyxeos) induction||No mapping|
|IMC-F106C-101 IMC-F106C monotherapy (Trial)||No mapping|
|Docetaxel Carboplatin Phesgo SC (adjuvant) CrCl||No mapping|
|Capecitabine (1250)||No mapping|
|Paclitaxel weekly Carboplatin weekly (CrCl)||No mapping|
|Bevacizumab Paclitaxel Carboplatin 21 day (CrCl) (ovarian/fallopian/peritoneal)||No mapping|
|Isatuximab Pomalidomide Dexamethasone (EAMS)||No mapping|
|Docetaxel Carboplatin Pertuzumab Trastuzumab IV(neoadjuvant node neg/unknown)Cr||No mapping|
|Vyxeos (Daunorubicin / Cytarabine) liposomal induction||No mapping|
|Paclitaxel Carboplatin EC (CrCl)||No mapping|
|Brentuximab vedotin Cyclophosphamide Doxorubicin Prednisolone (Bv-CHP)||No mapping|
|Thiotepa Fludarabine Treosulfan (Cord transplant)||No mapping|
|Chlorambucil-R (days 1 to 7)||No mapping|
|Ipilimumab Nivolumab (mesothelioma) (EAMS)||No mapping|
|Darolutamide Docetaxel Prednisolone (ORBIS)||No mapping|
|P+R-ICE Arm B Pembrolizumab R-ICE (Trial)||No mapping|
|Cemiplimab (support)||No mapping|
|ECF Daypt||No mapping|
|Gemcitabine (1200) Carboplatin (CrCl) (NSCLC/SCLC)||No mapping|
|Bendamustine-R Polatuzumab (not BMT candidate)||No mapping|
|EC Docetaxel Phesgo SC (adjuvant)||No mapping|
|ENRICH Bendamustine-R (NCRN Trial)||No mapping|
|Temozolomide (brain) (support)||No mapping|
|Daunorubicin liposomal Cytarabine liposomal (Vyxeos) consolidation||No mapping|
|Doxorubicin Dexrazoxane||No mapping|
|GO42661 Atezolizumab Bevacizumab/placebo Gemcitabine Cisplatin (Trial)||No mapping|
|Doxorubicin (sarcoma)||No mapping|
|daNIS-3 NIS793 Tislelizumab mFOLFOX Bevacizumab (Trial)||No mapping|
|ONC001 2 weekly IV monotherapy (Trial)||No mapping|
|Carboplatin Etoposide (oral etoposide days 2 and 3) (CrCl)||No mapping|
|Cyclophosphamide Fludarabine Thiotepa TBI RIC (Cord transplant)||No mapping|
|Gemcitabine (1200) Carboplatin (CrCl)||No mapping|
|Goserelin||No mapping|
|Pembrolizumab Paclitaxel Carboplatin EC (neoadjuvant then adjuvant) (EDTA)||No mapping|
|VTDPACE||No mapping|
|Carboplatin Etoposide (CrCl)||No mapping|
|Oxaliplatin Capecitabine (CapOx)||No mapping|
|Gemcitabine (1000) Cisplatin (70 split)||No mapping|
|Carboplatin (High grade glioma)||No mapping|
|Gemcitabine (1000) Cisplatin (25) daypt||No mapping|
|EC Docetaxel Pertuzumab Trastuzumab IV (neoadjuvant node positive)||No mapping|
|Cisplatin (50) Etoposide (50) (NSCLC) Daypt||No mapping|
|COSI Thiotepa Busulphan Fludarabine ATG (TBF) (Trial)||No mapping|
|Bortezomib Cyclophosphamide daily Dexamethasone||No mapping|
|Bortezomib daily Cyclophosphamide Dexamethasone (Amyloidosis)||No mapping|
|Docetaxel Carboplatin Pertuzumab Trastuzumab (neoadjuvant)||No mapping|
|Temozolomide (astrocytoma)||No mapping|
|Lutetium-177 oxodotreotide (without support medication)||No mapping|
|Carboplatin Etoposide (CrCl) (Oral etoposide days 2+3)||No mapping|
|SCALOP-2 Gemcitabine Paclitaxel albumin bound (NCRN Trial)||No mapping|
|Darolutamide (non-metastatic) (support)||No mapping|
|Pembrolizumab Paclitaxel Carboplatin EC (neoadjuvant then adjuvant)||No mapping|
|Daratumumab SC Lenalidomide Dexamethasone||No mapping|
|Anti-thymocyte globulin (ATG) equine (aplastic anaemia)||No mapping|
|Gemcitabine (1000) Carboplatin (CrCl) (ovarian)||No mapping|
|Abiraterone Prednisolone||No mapping|
|Liposomal doxorubicin (sarcoma)||No mapping|
|Pembrolizumab Paclitaxel Carboplatin EC (neoadjuvant then adjuvant) (CrCl)||No mapping|
|Paclitaxel weekly Pertuzumab Trastuzumab IV (adjuvant use only)||No mapping|
|Cabozantinib (RCC)||No mapping|
|Pertuzumab (neoadjuvant)||No mapping|
|Cabozantinib (compassionate use)||No mapping|
|Cisplatin Dexamethasone Gemcitabine PEG-Asparaginase (DDGP)||No mapping|
|ASTX727-02 ASTX727 then Decitabine (Trial)||No mapping|
|Cabazitaxel||No mapping|
|EC Docetaxel Pertuzumab Trastuzumab IV (neoadjuvant node negative / unknown)||No mapping|
|Paclitaxel Ifosfamide Cisplatin (TIP)||No mapping|
|Gemtuzumab Daunorubicin Cytarabine consolidation||No mapping|
|BGB-3111-LTE1 Zanubrutinib (Trial)||No mapping|
|Cyclophosphamide Etoposide Procarbazine Prednisolone maintenance (PEP-C)||No mapping|
|Carfilzomib Lenalidomide Dexamethasone (CarLenDex)||No mapping|
|Palbociclib||No mapping|
|Carboplatin Fluorouracil (CrCl) (H&N) daypt||No mapping|
|Neratinib||No mapping|
|Bevacizumab (7.5mg/kg) Paclitaxel Carboplatin (CrCl) (ovarian)||No mapping|
|Thiotepa Busulfan Fludarabine ATG (Allograft)||No mapping|
|Topotecan (oral)||No mapping|
|Fludarabine TBI post transplant Cyclophosphamide MUD||No mapping|
|Cyclophosphamide Dexamethasone Rituximab (DRC)||No mapping|
|Sorafenib||No mapping|
|Bortezomib weekly Cyclophosphamide Dexamethasone||No mapping|
|EC Docetaxel Pertuzumab Trastuzumab (neoadjuvant node positive)||No mapping|
|Paclitaxel weekly Phesgo SC (adjuvant use only)||No mapping|
|Daratumumab SC Bortezomib Thalidomide Dexamethasone||No mapping|
|Bortezomib||No mapping|
|Gemcitabine (1000) Carboplatin (CrCl)||No mapping|
|TOPAZ-1 Gemcitabine Cisplatin Durvalumab / placebo (Trial)||No mapping|
|Ifosfamide Etoposide (5 day)||No mapping|
|Bevacizumab (15mg/kg) Paclitaxel Carboplatin (CrCl) (ovarian)||No mapping|
|Darolutamide Docetaxel Prednisolone||No mapping|
|Carboplatin Paclitaxel Trastuzumab (GOJ) (CrCl)||No mapping|
|Cisplatin (75) Etoposide (100) (Neuroendocrine) daypt||No mapping|
|VIP Cisplatin Etoposide Ifosfamide||No mapping|
|Gemcitabine (1000) Cisplatin (70) daypt||No mapping|
|Daratumumab SC||No mapping|
|Docetaxel Carboplatin Pertuzumab Trastuzumab (neoadjuvant node positive) CrCl||No mapping|
|Gemcitabine (1000) Cisplatin (70)||No mapping|
|Cyclophosphamide Etoposide Procarbazine Prednisolone induction (PEP-C)||No mapping|
|Paclitaxel weekly Phesgo SC (following completion of EC cycles)||No mapping|
|Fludarabine Cyclophosphamide Alemtuzumab (Aplastic Anemia) (Allograft)||No mapping|
|Trabectedin (sarcoma)||No mapping|
|Midostaurin Daunorubicin Cytarabine||No mapping|
|Olaparib TABLETS (300mg bd)||No mapping|
|Docetaxel Fluorouracil Oxaliplatin (FLOT)||No mapping|
|Temozolomide 150/200||No mapping|
|Gemcitabine (1000) Cisplatin (25)||No mapping|
|Ribociclib||No mapping|
|Nivolumab Vinorelbine (oral) Carboplatin (neoadjuvant) (CrCl)||No mapping|
|Docetaxel Carboplatin Pertuzumab Trastuzumab IV (neoadjuvant node positive)CrCl||No mapping|
|Daratumumab SC Pomalidomide Dexamethasone||No mapping|
|Darolutamide (non-metastatic)||No mapping|
|Docetaxel Carboplatin Pertuzumab Trastuzumab (neoadjuvant node neg/unknown)CrCl||No mapping|
|Trabectedin||No mapping|
|Gemcitabine (lymphoma)||No mapping|
|Lenvatinib (Thyroid)||No mapping|
|Olaparib (adjuvant)||No mapping|
|Liposomal doxorubicin (support)||No mapping|
|Streptozocin Capecitabine||No mapping|
|EC Docetaxel Pertuzumab Trastuzumab (neoadjuvant node negative / unknown)||No mapping|
|UKALL 60+ Arm B Intensification (off study)||No mapping|
|Aprepitant oral||No mapping|
|MATRIX NLMT Arm C (Palbociclib) (Trial)||No mapping|
|Momelotinib (Compassionate Use)||No mapping|
|Trastuzumab SC 21 day (support)||No mapping|
|EP||No mapping|
|LUD2015-005 Cohort D2 (NCRN Trial)||No mapping|
|CT7001-001 Module 4 Cycle 1 onwards (Trial)||No mapping|
|Atezolizumab 28 day (relapsed/metastatic)||No mapping|
|Constellation (0610-02) Arm 3 CPI-0610 125mg + Rux R(-1) (Trial)||No mapping|
|Cisplatin hydration (cisplatin dose 41-60mg/m2)||No mapping|
|NUTIDE 302 Cohort 1c NUC-3373 + LV (Trial)||No mapping|
|ALKS 4230-006 ARTISTRY-6 cohort 2 (Trial)||No mapping|
|OCTOVA Arm B (NCRN Trial)||No mapping|
|UKALL 60+ Arm B and D Maintenance (off study)||No mapping|
|PLATFORM Arm A3 MEDI4736 maintenance (NCRN Trial)||No mapping|
|Cisplatin weekly (ovarian) daypt||No mapping|
|RXC004/0001 (Trial)||No mapping|
|Aprepitant Dexamethasone (day 1 on ward)||No mapping|
|CXD101-0901; CXD101 expansion (early phase trial)||No mapping|
|Samuraciclib (compassionate use)||No mapping|
|D933LC00001 (BEGONIA) Arm 7 (Trial)||No mapping|
|MITHRIDATE (RG_16-148) Hydroxycarbamide (Trial)||No mapping|
|EDP daypatient||No mapping|
|ADCT-301-201 (Trial)||No mapping|
|NUTIDE 701 weekly (Trial)||No mapping|
|CompARE Arm 1 Cisplatin 40mg/m2 (NCRN Trial)||No mapping|
|WO41554 (Trial)||No mapping|
|PETRA (D9720C00001) Module 1 (Trial)||No mapping|
|Mifamurtide (support)||No mapping|
|RP3-301 RP3 monotherapy cohorts 3 and 4 (Trial)||No mapping|
|2102-HEM-101 FT-2102 twice daily (Trial)||No mapping|
|ACE-536-MDS-001 (MEDALIST) (NCRN Trial)||No mapping|
|UKALL 14 Imatinib (NCRN Trial)||No mapping|
|RP3-301 RP3 Nivolumab (Trial)||No mapping|
|Nivolumab 28 day (relapsed/metastatic)||No mapping|
|UKALL 2011 Regimen B Standard interim maintenance (off study)||No mapping|
|ADVANCE Group 2 (Trial)||No mapping|
|LOXO-BTK-18001 (Trial)||No mapping|
|Sodium choride 0.9% 1000ml IV infusion over 60 minutes||No mapping|
|ONC001 Part B (Trial)||No mapping|
|Cetuximab / Panitumumab skin toxicity||No mapping|
|AMMO Arm A ASTX727 (Trial)||No mapping|
|ALKS 4230-006 ARTISTRY-6 cohort 1 (Trial)||No mapping|
|RS-TS-101-01 (Trial)||No mapping|
|Dapsone||No mapping|
|Paracetamol IV||No mapping|
|CHARIOT M6620 Tuesday doses (Trial)||No mapping|
|NUTIDE 301 part 1 (NUC-3373 weekly) (NCRN Trial)||No mapping|
|RADAR (Myeloma XV) RCyBorIsaD (Trial)||No mapping|
|Rituximab IV 100mg (ITP)||No mapping|
|Cardamon consolidation (CarCyDex) (NCRN Trial)||No mapping|
|IMG-7289-CTP-201 IMG-7289 (Trial)||No mapping|
|IMP-MEL IMM60 Pembrolizumab (Trial)||No mapping|
|Venetoclax doses for delay in titration (add in on date of delay) (support)||No mapping|
|DREAMM-9 Belantamab mafodontin Rd maintenance (Trial)||No mapping|
|BGB-3111-302 BGB-3111 (NCRN Trial)||No mapping|
|Mouth and Bowel Support Minus Metoclopramide||No mapping|
|DREAMM-9 Belantamab mafodontin VRd (Trial)||No mapping|
|CHARIOT M6620 Friday doses (Trial)||No mapping|
|Ipi-Glio Arm B (Trial)||No mapping|
|Aprepitant already has antiemetic dexamethasone prescribed (day 1 on ward)||No mapping|
|Cisplatin hydration daypatient||No mapping|
|Hydroxycarbamide (3 months)||No mapping|
|RXC004/0001 Module 2 (Trial)||No mapping|
|ASTX660-01 (7 days on/7 days off) (Trial)||No mapping|
|Lansoprazole 5 day||No mapping|
|UCL/17/0629 (PROMPT) Pembrolizumab (Trial)||No mapping|
|Aprepitant already has antiemetic dexamethasone prescribed (day 1 at home)||No mapping|
|BP42675 RO7122290 Cibisatamab part 1 (Trial)||No mapping|
|GCSF lenograstim||No mapping|
|MidAC||No mapping|
|GS-US-352-4365 (Trial)||No mapping|
|MIV-818-101/201 (Trial)||No mapping|
|DS3201-A-U202 (Valentine) (Trial)||No mapping|
|SCIB1-002 Pembrolizumab SCIB1 (Trial)||No mapping|
|NG-350A-02 (FORTIFY) NG-350A Pembrolizumab (Trial)||No mapping|
|LOXO-BTK-20019 Arm A LOXO-305 (Trial)||No mapping|
|MOTION Vismeltinib / placebo (Trial)||No mapping|


* `Regimen` Cancer treatment regimen 

```sql
select 
	distinct
	    NHS_Number,
	    Start_Date_Of_Regimen,
	    trim(Regimen, ' =') as Regimen,
from omop_staging.sact_staging
	
```


[Comment or raise an issue for this mapping.](https://github.com/answerdigital/oxford-omop-data-mapper/issues/new?title=OMOP%20Episode%20table%20episode_object_concept_id%20field%20SACT%20Episode%20mapping){: .btn }
